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Abstract 
PREPARATION AND CHARACTERIZATION OF ELECTROSPUN POLY(D,L-LACTIDE-
CO-GLYCOLIDE) SCAFFFOLDS FOR VASCULAR TISSUE ENGINEERING AND THE 
ADVANCEMENT OF AN IN VITRO BLOOD VESSEL MIMIC 
Tiffany Richelle Peña 
 Currently, an estimated 1 in every 3 adult Americans are affected by one or more 
cardiovascular complications.  The most common complication is coronary artery disease, 
specifically atherosclerosis.  Outcomes of balloon angioplasty treatments have been significantly 
improved with the addition of drug eluting stents to the process.  Although both bare metal and 
drug eluting stents have greatly increased the effectiveness of angioplasty and decreased the 
occurrence of restenosis, several complications still exist.  For this reason, the stent industry is 
continually advancing toward better stent and drug-eluting designs, deployment methods, and 
adjuvant drug therapies, necessitating fast, reliable pre-clinical test methods.  Recently, 
advancements in tissue engineering have led to the development of an in vitro blood vessel 
mimic (BVM) and the feasibility of evaluating cellular response to intravascular device 
implantation has been demonstrated.  There are several physiological and scalability limitations 
of the current BVM model that must be addressed before effective use of the model can be 
initiated.   The limiting aspect addressed in this thesis is the use of expanded 
poly(tetrafluorethylene) [ePTFE] scaffolding for the development of the BVM.  There are 
several disadvantages and limitations to ePTFE including high cost and non-native mechanical 
properties.  The ability to produce and tailor scaffolds in-house would greatly impact the 
scalability, cost effectiveness, and control over scaffold properties for BVM optimization.  Also, 
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in-house fabrication will open up further avenues of research into optimum scaffold design for 
better cellular responses when cultured in vitro. 
  Electrospinning is a relatively simple and economical method of creating tissue 
engineering constructs with micro-architecture similar to the native extracellular matrix.  Based 
on the clinical problem and the potential for the BVM, the aim of this thesis is to employ 
electrospinning for the development of poly(D,L-lactide-co-glycolide) [PLGA] vascular 
scaffolds as a replacement to ePTFE for the BVM.  After primary literature review, PLGA was 
determined an advantageous polymer for tissue engineering vascular scaffolds and 
electrospinning based on evidence of adequate endothelial cell attachment, mechanical properties 
similar to the native vessels, controlled degradation, and good biocompatibility.  The first phase 
of this thesis was to develop an acceptable protocol for the fabrication of electrospun PLGA 
scaffolds by varying solution concentration, flow rate and applied voltage.  Electrospun solutions 
of 15 wt% PLGA in CHCl3 resulted in continuous un-beaded fibers of 5-6 microns and tensile 
properties (3-5 MPa) similar to the native vessel.  The optimum protocol for electrospinning 15 
wt% PLGA incorporated a flow rate of 5.5 ml/hr and an applied voltage of 12,000 V.  In the 
second phase of this thesis, final protocol PLGA scaffolds were cultured in vitro with human 
umbilical vein endothelial cells (HUVECs) up to 6 days.  Fluorescent microscopy and SEM 
analysis suggest the porous nature of the scaffolds was conducive to sub-luminal cellular 
penetration.  Although results were not optimal for developing an endothelium for the ideal 
BVM design, the potential of using electrospinning for in-house production of scaffolds for 
tissue engineering was established.  Further optimization of the electrospinning protocol to 
develop nano-sized structural features could enhance the ability to form an intimal lining of 
endothelial cells for the next generation BVM design.    
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Chapter 1 - Introduction 
1.1 Motivation 
The introduction of stents in 1987 for the treatment of atherosclerosis has drastically 
increased the effectiveness of traditional balloon angioplasty [1].  Since that time, stents have 
and are continually being developed and improved with advancements in areas of architecture, 
drug-eluting designs, deployment methods, and adjuvant drug therapies [2].  With each new 
design, the need for fast, reliable data is imperative to move these devices to the market.  
Although in vivo animal models for stenting and angioplasty have been developed and 
extensively utilized, time, money and animal numbers could be reduced by implementing a test 
model that simulates the human physiological condition in vitro.     
An in vitro “blood vessel mimic” (BVM) that utilizes tissue engineering techniques has 
been demonstrated as a method for evaluating endothelialization of  bare metal stents [3].  
Although the primary focus of tissue engineered vascular grafts (TEVGs) has been replacement 
and bypass therapy for damaged or blocked blood vessels, tissue engineering blood vessels for 
the BVM is a promising alternative application that could have substantial impact on early 
intravascular device evaluation and development prior to animal and clinical trials.   
The current BVM model has several physiological and mechanical limitations as well as 
scale up limitations.  Presently, the BVM is made of a biocompatible, non-biodegradable 
expanded poly(tetrafluoroethylene) [ePTFE] scaffold.  The scaffold is critical to proper tissue 
development and simulation of the native vessel, but there are several disadvantages associated 
with ePTFE.  Disadvantages include high cost, poor mechanical compliance and inability to 
tailor morphological and mechanical properties specific for the BVM application.  Consequently, 
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the aim of this thesis is to determine an alternative scaffolding material that could improve the 
BVM model and eliminate some of the current scaffolding limitations.   
The following sections of this Introduction will provide the background and foundation 
on which this thesis is based.  A review of coronary artery disease and treatments, including 
bypass grafting, angioplasty, and stenting will be presented.  A summary of TEVGs and the 
importance of scaffolding for successful construct development, as well as the application of 
tissue engineered blood vessels for in vitro device evaluation, will be provided.  The Introduction 
will include a review of electrospinning, the polymer scaffold fabrication technique utilized in 
this thesis, including history, theories, and process parameter optimization specifically for TEVG 
development.  The Introduction will conclude with a summary of the overall goals and objectives 
for this thesis. 
1.2 Cardiovascular Disease 
According to the 2009 American Heart Association’s (AHA’s) update on Heart Disease 
and Stroke Statistics, 1 in 3 adult Americans (approximately 80 million people) are currently 
affected by 1 or more types of cardiovascular diseases (CVDs).  Leading as the number one 
cause of death in America, CVD is responsible for 2,400 fatalities per day which corresponds to 
1 death every 37 seconds in the United States [4].  
Coronary artery disease (CAD), also known as coronary heart disease (CHD), caused 1 in 
5 deaths in the United States in 2005 and is the leading CVD killer for all American men and 
women.  In 2008 the cost for treating CHD was estimated at $156.4 billion [4].  CHD is strongly 
equated with atherosclerosis (Figure 1), which occurs when coronary arteries are blocked by 
plaque, thus restricting necessary blood flow and leading to angina, shortness of breath, heart 
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attack, stroke and often death [5].  Device based treatments for CHD include bypass grafting, 
angioplasty and stenting.   
 
Figure 1 – Atherosclerosis is the buildup of plaque along the inner arterial wall.  Unstable 
plaque can rupture causing blood clots leading to heart attack or death.   
(Permission granted to reprint image from medmovie.com a division of Gersony Medical, Inc; 
See Appendix I) 
 
1.3 Treatment of Coronary Heart Disease 
Coronary heart disease can be treated by lifestyle modifications, medications and medical 
procedures.  The goal of each aforementioned prescribed treatment is to alleviate symptoms, 
slow the progression of disease, and repair or replace diseased tissue, respectively.  A brief 
introduction to coronary artery bypass procedures, angioplasty, and stenting will be provided 
within this section.  The purpose of this section is to introduce the reader to CHD treatments as a 
necessary foundation for intravascular device testing and tissue engineering.    
1.3.1 Coronary Artery Bypass Grafting 
Nearly 448,000 coronary artery bypass grafts (CABG) surgeries are conducted each year 
[4].  Coronary bypass surgery treats atherosclerosis by bypassing the diseased area using a 
natural or synthetic graft to reroute blood flow (Figure 2).  The procedure is highly invasive, 
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expensive and is associated with a long recovery time; however, CABG is highly successful long 
term, with lower mortality rates, less angina, and fewer revascularization procedures compared 
to alternative methods [6].     
 
Figure 2 - The above illustration shows a bypass graft rerouting blood flow around the 
diseased region of the coronary artery.  The graft is connected from the aorta to the distal 
part of the epicardial coronary arteries.  
(Permission granted to re-print image from medmovie.com a division of Gersony Medical 
Media, Inc.; See Appendix I) 
 
Biological vascular grafts can be classified as autografts, allografts or xenografts.  
Autografts are transplanted grafts from one part of the body to another within the same 
individual.  The standard choice of autologous grafts for CABG surgery is either the internal 
mammary artery (IMA) or the greater saphenous vein [7], however the radial artery and lesser 
saphenous vein and others have been used.  IMA grafts are superior to saphenous vein grafts 
(SVG) with twice the patency for a 10 year period [7, 8].  During coronary bypass surgery, the 
replacement vessel is cut out of the chest, arm, or leg and is connected from the side of the 
coronary artery to the aorta, as shown above in Figure 2.  Autografts will not likely elicit an 
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immune response and therefore, are the optimum choice for bypass surgery.  However, patients 
needing replacement therapy often lack the necessary healthy autologous vessel.  An estimated 
60% of all patients in need of bypass surgery do not have a vessel suitable for grafting, mainly 
due to pre-existing diseases and conditions, such as, intrinsic venous disease, varicose vein 
ligation, prior myocardial revascularization and previous peripheral arterial reconstruction [9].  
Consequently, if no suitable autologous conduit exists, alternative non-autologous conduits can 
be used.  
Allografts are donated vessels from one individual to another of the same species.  
Allografts present high risks associated with immune rejection, but a close genetic match can 
increase patency.  Patients who receive donor constructs will remain on immunosuppressive 
drugs to prevent the chance of transplant rejection.  Unfortunately, the number of graft donors 
does not meet the high demand for replacement conduits, and often those on the wait list die 
before an acceptable donor has been matched [10].  This severe shortage in donor tissue has lead 
to the exploration of xenografts.   
Xenografts are donated vessels from a different species.  The genetic disparity between 
human host and xenograft is maximized and such grafts will elicit rejection immediately.  Small 
progress has been made with porcine vessels, which are most similar to the human vessel in 
physiology and size [11].  Still, with the implementation of xenografts the need for 
immunosuppressive drugs, in order to stop immediate rejection by the host, is a costly and 
crucial necessity.  With the many limitations associated with biological grafts for coronary artery 
bypass surgery, synthetic grafts have been developed as a possible alternative to alleviate 
symptoms and to treat CAD.  
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Advantages of synthetic grafts over biologic grafts as replacement conduits include: cost, 
availability, and the potential to tailor physical properties to match patient conditions (e.g. size 
and shape).  The most widely used synthetic biomaterials for peripheral bypass surgery are 
poly(ethylene terephthalate) [PET or Dacron] and expanded poly(tetrafluoroethylene) [ePTFE or 
GORE-TEX®], both of which have been clinically tested with successful outcomes for large 
diameter (> 6 mm) vascular grafts.  However, these synthetic replacements in small diameter 
sites, with lower blood flow velocities, have resulted in thrombosis rates of nearly 40% in just a 
few months [10-13].  The primary disadvantages of synthetic grafts leading to graft failure are 
the lack of an appropriate endothelium on the lumen of the graft, and compliance mismatch [12].  
Often, compliance mismatch in synthetic vascular grafts is associated with the onset of intimal 
hyperplasia and aneurysm development, resulting in graft failure [13-16].  Consequently, in vitro 
surface endothelialization of Dacron and ePTFE has been shown to significantly increase the 
anti-thrombogenicity of grafts in vivo [17, 18].  Other experimental methods of increasing 
synthetic vascular graft patency include heparinization, chemical modifications, and various 
protein coatings [19-21].  Although there have been significant improvements in these grafts, 
surface modifications in each of the aforementioned studies typically lead to clotting, intimal 
hyperplasia, and ultimately, bypass graft failure [17, 19, 20].  Still, compliance mismatch with 
ePTFE and PET has not been resolved.  Other major complications sometimes associated with 
synthetic grafts include infection, periprosthetic fluid collection, and structural degeneration 
[22].  Finally, both natural and synthetic grafts often require revision surgery [23].  Limitations 
in natural and synthetic grafts and the invasiveness of CABG surgery make angioplasty a highly 
desirable alternative treatment to CHD.       
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1.3.2 Angioplasty and Stenting 
 Percutaneous coronary intervention (PCI), or angioplasty, treats atherosclerosis by 
inflating a balloon inside the blocked region of the artery to push or break the plaque against the 
arterial wall, reopening the lumen for blood to flow (Figure 3).  The balloon is inserted through 
the use of a catheter usually by way of the femoral artery at the groin.  Balloon angioplasty is a 
minimally invasive procedure compared to bypass surgery; however, angioplasty is highly 
subject to re-narrowing of the arterial wall, most commonly referred to as restenosis.  According 
to the National Institute of Health, 4 out of 10 patients develop restenosis after angioplasty [24].  
Restenosis is believed to be the result of elastic recoil of the arterial wall and the formation of 
scar tissue due to vessel injury from balloon inflation [25].      
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Figure 3 - The figure shows a cross-section of the coronary artery with plaque buildup.  A 
deflated balloon is first inserted by way of a catheter into the diseased region (A).  The 
balloon is then inflated, pressing plaque against the arterial wall (B).  The balloon is 
removed and the widened artery restores blood flow (C).   
(Permission granted to re-print image from the National Heart, Lung, and Blood Institute as a 
part of the National Institute of Health and the U.S. Department of Health and Human 
Services; See Appendix I) 
 
Stenting is the process of deploying a wire mesh tube, or stent, to open an artery during 
balloon angioplasty (Figure 4).  The stent typically remains in the artery permanently to support 
blood flow and acts as a scaffold for endothelialization.  Stenting was first incorporated into PCI 
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procedures in 1987 and since then approximately 80% of all angioplasties are combined with 
stenting due to an outstanding reduction in restenosis rates from 30-40% to 15-20% [1].  
Specifically, stenting reduces restenosis by minimizing elastic recoil of the vessel, in addition to 
providing an anti-thrombogenic surface for blood to flow [1, 26]   
.  
Figure 4 - The figure shows a cross-section of the coronary artery with plaque buildup.  
The stent is mounted onto a balloon and inserted into the diseased region of the artery by 
way of a catheter (A).  The balloon and stent together are expanded, pushing the plaque 
against the arterial wall (B).  The stent remains as a permanent support in the vessel and 
the balloon is removed.  The widened artery restores blood flow (C). 
 
(Permission granted to re-print image from the National Heart, Lung, and Blood Institute as a 
part of the National Institute of Health and the U.S. Department of Health and Human 
Services; See Appendix I) 
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Serious complications remain associated with stenting, such as increased thrombosis and 
in-stent restenosis [25].  Increased thrombosis has been largely controlled through the use of 
anti-platelet therapy regimes with such drugs as aspirin, warafin, and heparin [27].  In-stent 
restenosis is explained as the arterial healing response due to balloon and stent expansion during 
angioplasty with a stent, in which case the blood vessel is damaged and consequently initiates 
cellular proliferation and intimal hyperplasia [1].  Given that the stent is typically permanent, 
introduction of the stent into the body leads to localized inflammatory responses and foreign 
body reactions that contribute to restenosis as well [28].  Many efforts have been made to reduce 
in-stent restenosis, with most recent efforts focusing upon drug-eluting and bioabsorbable stents. 
The goal of drug-eluting stents is to prevent narrowing of the arterial wall through the 
continuous release of medications or bioactive agents bound in the stent coating or matrix after 
implantation [29].  Bioactive agents are released into the blood stream and locally in tissue 
surrounding the stent [29].  Several advancements have been made and are continually being 
pursued and studied, including stent design, biodegradable polymers, coatings, medications, drug 
release rates and homogeneity, and dosages [1, 30].  With each new development, the need for 
intravascular device testing increases.  Given the high costs and controversy over validity of pre-
clinical animal testing, a more physiological in vitro testing system could provide faster and 
more reliable results prior to in vivo analysis.  Such a system will be described later in the 
Introduction of this thesis.       
1.4 Tissue Engineered Vascular Grafts (TEVGs) 
With the optimization of small diameter synthetic grafts far from ideal and the limited 
availability of autologous and allogenic vascular grafts, tissue engineering has emerged as a 
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means of potentially creating completely autologous tissue engineered blood vessels for small 
caliber vascular grafts.  This section of the Introduction will provide a basic overview of tissue 
engineering, specifically TEVGs as an alternative to standard CABGs.  A more detailed review 
of the importance of scaffolding during the development of TEVGs will be provided.   The end 
of this section will introduce the reader to previous work on a TEVG-based in vitro testing 
system for intravascular devices.  The system was developed through the concept of tissue 
engineering blood vessels and is the primary application for the work of this thesis. 
1.4.1 History of Tissue Engineering 
The concept of tissue engineering was first applied in the 1980’s and since then the 
number of tissue engineered applications and investigations has increased with enthusiasm 
among both engineers and scientists.  Many tissue engineered constructs have undergone clinical 
trials and some are already on the market.  Areas of tissue engineering exploration involve 
fabricated skin [31], liver [32], pancreas [33], intestines [34], esophagus [35, 36], nerves [37], 
cartilage [38-40], bones [40, 41], ligaments [42, 43] and tendons [43, 44].  Significant 
contributions have also been made in the cardiovascular area, specifically valve leaflets [45, 46] 
and blood vessels [47-50].   
Tissue engineering can be defined as the combination of engineering and biologic 
principles to generate or repair tissue or organs through the cultivation of cells on a scaffold in 
vitro, for transplantation into the appropriate anatomical region of a diseased patient [22].  The 
goal of tissue engineering is to recreate or mimic human tissue, either in whole or in part, in 
vitro, using autologous cells.  Ideally, using the patient’s own cells will allow the construct to 
function appropriately without rejection.  In theory, cells are isolated from the patient and 
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expanded in cell culture to be seeded onto a scaffold or artificial extracellular matrix (ECM).  
Scaffold and cells together are then typically matured in a bioreactor, which is a device used to 
transport nutrients and oxygen, maintain concentration levels, impart mechanical and electrical 
stimulus to imitate the body, control environmental conditions (e.g. pH, temperature, CO2 levels, 
growth factors, gradients etc.) and induce homogenous cell distribution.  Barron et al. 
generalized the bioreactor as a simulated biological environment where “in vivo biomechanical 
and biochemical conditions are created in vitro for functional tissue development” [23].  Once 
the tissue engineered construct has been developed the construct is implanted into the patient 
where remodeling results in the construct becoming fully functional within the body and 
surrounding tissues [22].   
1.4.2 Mimicking the Human Blood Vessel 
The need for small-diameter vascular bypass conduits has driven the development of 
tissue engineered vascular grafts (TEVGs).  In order to produce a TEVG, the anatomy, function 
and properties of the human vessel must be considered.  This section will outline the basic 
anatomy and function of the blood vessel and how each component is simulated or created by 
general tissue engineering techniques. 
There are three distinct layers of arteries; the tunica intima, tunica media, and tunica 
adventitia, which together surround the vessel lumen, or the space containing blood.  The intima, 
closest to the lumen, is made of a continuous layer of endothelial cells (ECs) responsible for 
creating a frictionless surface for unhindered blood flow and prohibiting platelet activation.  The 
internal elastic lamina separates the intima from the media.  In TEVGs, ECs are harvested from 
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vessels or obtained as derivatives of endothelial progenitor cell lines [51] and are used to 
engineer the luminal layer of cells on a scaffold in vitro.     
The media, middle layer, is composed of a dense population of smooth muscle cells 
(SMCs) within a surrounding ECM.  The ECM is composed of collagen types I and III and 
elastin fibers, and is responsible for vasoconstriction or vasodilatation in order to maintain 
necessary blood pressure and blood flow.  The external elastic lamina separates the media from 
the adventitia.  For a TEVG, the properties of the media may be provided by the scaffold 
material.  However, SMCs can be used for developing the media of a TEVG.  L’Heureux et al. 
cultured sheets of vascular SMCs and placed these sheets around a tubular support device.  After 
maturation the support was removed and endothelial cells were seeded on the lumen, thus 
producing a scaffold-free functional vessel [52].   
The adventitia is largely composed of fibroblasts and an ECM of loosely woven collagen 
and elastin [53].  Collagen, specifically, provides the stiffness and high tensile strength necessary 
for vessel protection and structural integrity, whereas elastin, in both the media and adventitia, 
contributes to the compliance of the vessel in response to arterial pulsation.  In general, the 
scaffold used to tissue engineer blood vessels acts as both the media and adventitia.  In some 
instances, sheets of fibroblasts wrapped around the scaffold have been used to simulate the 
adventitia [54].  However, in most cases, the scaffold is the major structural component that 
provides the mechanical properties of both the media and adventitia of the native vessel.   
Requirements of TEVGs are not limited to simply mimicking the native blood vessel 
anatomy.  In order to truly mimic the native blood vessel, TEVGs must contain a confluent and 
adherent layer of ECs and must have the mechanical properties necessary to maintain 
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compliance under pulsatile flow and structural integrity under increased pressures, properties  
provided by elastin and collagen in the ECM of the native vessel [55].  Additional requirements 
of an ideal TEVG include suture retention, kink resistance, manufacturability, cost-effectiveness, 
reproducibility in a variety of lengths and diameters, easy storage, and the ability to be produced 
in a reasonable amount of time [56].   
1.4.3 Scaffolds 
The interplay of cells and scaffolds is a critical component of tissue engineering.  The 
cellular component is responsible for the construct performing the same function as that of the 
tissue being replaced.  Cells are encouraged to develop into the proper phenotype and orientation 
largely by the scaffold they interact with and the environment in which they are maintained.  
This section is aimed at providing an overview of scaffold design for tissue engineered vascular 
constructs.  Details on scaffold morphology and mechanical behavior and the corresponding 
effects on cell interactions and final construct endpoints will be provided.   
        In general, tissue engineering utilizes a synthetic or natural, biodegradable three 
dimensional (3D) microporous scaffold, which is then cultivated with cells in a bioreactor in 
until a tissue construct is formed.  The most basic function of the scaffold is to provide 
mechanical stability and the overall shape, size and volume of the tissue construct being 
developed [57].  Scaffold morphologies are largely responsible for encouraging and promoting 
cellular adhesion and correct phenotype, thus guiding tissue development into the appropriate 
construct.  Generally, a biodegradable scaffold is desired such that all implanted materials will 
eventually be fully incorporated into the body and no foreign material will remain.  In such 
cases, resorption and degradation kinetics must be in balance with development and remodeling 
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capabilities of the cells in vivo or in vitro.  However, non biodegradable scaffolds are also 
desirable in cases where structural integrity must be maintained or when the host’s body is 
unable to form the necessary replacement tissue.  Degradation bi-products also play a role in the 
success and biocompatibility of a scaffold.  For a scaffold to be biocompatible, it must not elicit 
or encourage an undesirable tissue response or interrupt any physiological process in the host, 
while maintaining functionality, be it degradation or long term structural integrity [58].  
Therefore, during cell culture in vitro or implantation in vivo, scaffolds must either degrade, 
releasing non-toxic bi-products, or become incorporated into the tissue construct by mechanisms 
of remodeling [58].  Although some basic criteria have been outlined for scaffold-based tissue 
engineering, the requirements for scaffold design are largely tissue or organ and cell specific.   
Scaffolds for tissue engineering small caliber vascular grafts should provide both 
mechanical and functional support similar to the ECM until the cells are stabilized by the 
production of their own ECM.  The scaffold shape must be cylindrical, hollow and of a 
reasonable diameter (< 6 mm).  The scaffold micro-architecture must also mimic the specific 
tissue for which the final construct is intended to replace.  In native vessels, cells interact within 
a three-dimensional, fibrous ECM through which matrix morphology and mechanical behavior 
promotes cellular development [59].  Therefore, further requirements for a successful TEVG are 
found in the ECM mimicking micro-structural properties of the scaffold including porosity, pore 
size, and general architecture (fibrous, spherical voids etc.) [60].  Bio-mimicking the 3D ECM by 
fabricating fibrous scaffolds with nanometer fiber diameters enhances vascular endothelial and 
smooth muscle cell adhesion and proliferation in scaffolds, with fiber diameters in the range of 
50-500 nm [61, 62].  ECM protein fibers are 1 to 2 orders of magnitude smaller than the cells 
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they interact with, allowing cells to interact with several fibers at one time [58].  The scaffold 
should thus maximize available surface area to create a 3D network for cell interactions.   
Porosity, the percentage of pore space in a solid,  is necessary for nutrient and waste 
exchange and cell signaling [63].  Pore size is also critical for the migration and ingrowth of cells 
and the transport of proteins [63, 64].  There is however a delicate balance.  If the pore sizes are 
too large (>10 µm), cells will be unable to find enough surface area for successful attachment 
and if the pores are too small (< 10 µm), cells will be hindered from necessary migration into the 
scaffold.  Furthermore, high porosity (> 90%) will promote increased cell infiltration.  However, 
there is a corresponding decrease in mechanical strength by a power-law relationship [65].  Pore 
interconnectivity is also important as it allows for cell migration and ECM infiltration.  
Generally, without pore interconnectivity, a porous scaffold would serve no purpose.  An ideal 
scaffold would have 100% pore interconnectivity to maximize the transport of nutrients 
throughout the construct [59]. 
In summary, ideal scaffolds for TEVGs will be physiological representatives of the native 
blood vessel in strength and architecture, with a high surface to volume ratio to facilitate cell 
attachment, differentiation, communication and circulation of all necessary nutrients, waste and 
growth factors.   
1.4.4 Progress in TEVG Development  
TEVGs have been developed using a variety of materials, cells, and bioreactor designs.  
The first engineered vascular construct was developed by Weinberg and Bell who developed a 
tubular vessel out of bovine ECs, SMCs and fibroblasts surrounded in a Dacron sleeve for 
added strength [66].  Since then, both natural and synthetic materials have been used for 
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TEVGs.  Niklason et al. developed TEVGs using polyglycolic acid (PGA) scaffolds seeded 
with vascular SMCs and ECs, cultured in a pulsatile perfusion bioreactor.  These tissue 
engineered constructs were implanted in swine with patency up to 24 days [67].  L’Heureux et 
al. showed the feasibility of generating a completely biological TEVG from human cells and 
was able to create all three layers of the blood vessel; intima, media and adventitia.  Analysis of 
these TEVG’s showed the graft had appropriate mechanical strength and a confluent 
endothelium was achieved, however burst pressure was much higher than the native artery [52, 
54].   
A variety of bioreactors have been used to stimulate culture environments such as 
pulsatile perfusion bioreactors, rotating vessel chambers, and continuous flow systems.  Each 
type of bioreactor is used to stimulate a certain cellular function.  To date, there is no 
scaffold/cell/bioreactor/stimulation system that has overcome the challenges of creating small 
diameter TEVGs to meet all the requirements for a successful vessel mimicking construct for 
implantation.  Although a successful TEVG for replacement or bypass therapy has not been 
developed, the progress that has been made has opened up many doors to other scientific 
investigations [54].  One such avenue of TEVG application is to provide an in vitro model for 
device testing. 
1.4.5 Blood Vessel Mimic as an In Vitro Vessel Model 
In 2006, Cardinal et al. published work on the ability to use TEVGs in vitro to test the 
response of an intimal lining of endothelial cells to stent implantation [3].  The study suggests 
assessment of new stent configurations and designs in an in vitro tissue model would provide 
more physiological, cost effective, high throughput and convenient results of cellular-device 
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interactions prior to pre-clinical animal testing.  The study used human endothelial cells from 
adipose tissue pressure sodded on the lumen of an ePTFE scaffold.  Cells and scaffold are 
matured in a flow bioreactor until a confluent cell lining has been developed on the inside of the 
ePTFE.  The model consists of a rectangular vessel chamber (Figure 5), a media reservoir and a 
peristaltic pump.  Stents were deployed into tissue lined scaffolds within the bioreactor and 
endothelialization was observed.  Such endothelialization was consistent with what results 
obtained for animal studies of bare metal stent designs [3, 68].  The study shows the feasibility of 
using a blood vessel mimic (BVM) with a human cell lining to quantitatively evaluate the tissue 
response to stents in vitro. 
 
Figure 5 – The Blood vessel mimic (BVM) system above is made of a polymer casing with a 
lid that attaches with screws.  The scaffold is pushed onto the two fittings inside the 
chamber and sutured in place. 
 
One of the major advantages to the BVM design is the ability to produce a consistent, 
controlled model for directly comparing and evaluating several stent designs.  There are 
however, several physiological and mechanical limitations to the BVM system at this time.  The 
system utilizes a peristaltic pump which provides media flow but does not account for the 
pressures, pulsatility, and fluid shear stress experienced by the native vessel.  Also, the BVM 
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does not contain a media or adventitia layer and therefore smooth muscle cell and contractility 
responses of the vessel due to stent implantation, specifically drug eluting stents, could not be 
evaluated [3].  Furthermore, while the BVM system uses nutrient rich media, the use of blood 
could possibly give insight into the relation between blood flow and development of restenosis 
[3].  There are other limitations and disadvantages to be addressed including scalability and user 
friendliness.  One major limiting factor of the BVM is the use of ePTFE.  Primary disadvantages 
to using ePTFE are the high cost, the dependency on ePTFE suppliers, and non-native 
mechanical properties, as discussed previously in the Introduction of this thesis.      
Currently, under the guidance of Dr. Kristen Cardinal of California Polytechnic State 
University, several lab researchers are working toward making a more physiological, user 
friendly, high-throughput and cost effective BVM system.  The latest version of the BVM 
bioreactor is shown in Figure 6.  The modified system allows for more simplicity, ease of 
assembly, and accommodation of varying sized scaffolds and vessel morphologies.  The new 
BVM system utilizes a leak-proof snap and seal container for the vessel chamber.  This update 
allows for easy access to and insertion of the scaffold in the bioreactor.  New adjustable length 
fittings to accommodate varying length scaffolds and stents were added as well.  With the new 
system design, introduction of pulsatility and wall shear stress to better simulate in vivo 
conditions of the native blood vessel are being investigated.  Incorporation of SMCs, in addition 
to ECs, to create the media of the blood vessel is also being investigated.   
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Figure 6 - The leak proof polypropylene container allows more room for scaffold insertion.  
The container uses adjustable fittings for different length scaffolds.  The above image 
shows ePTFE sutured onto the fittings inside the new bioreactor chamber.  The system 
contains a media reservoir and is can be hooked up to a pulsatile perfusion pump. 
 
To address the limitations of ePTFE, a need exists for a scaffold that better represents the 
native vessel in mechanical behavior (i.e. tensile strength, elastic modulus) and architecture, 
which can be developed in-house, and is less expensive.  The desire to mimic the native blood 
vessel is imperative to proper TEVG development and such mimicking behavior can be achieved 
through material selection and processing.  Different biomaterials can be formed into different 
3D morphologies by various processing techniques and can achieve a range of material 
properties.  Some fabrication techniques used to develop porous tissue engineering scaffolds 
include, gas foaming [69, 70], solvent casting and particulate leaching [71, 72], fiber bonding 
[73], extrusion [74], solvent induced phase separations [75, 76], rapid prototyping [44] and 
freeze drying [77]. One such fabrication method known as electrospinning, although still in 
developmental infancy, is a relatively simple, cost effective process of routinely creating 
Media Reservoir 
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continuous micron to nano-sized fibers in a highly porous network similar to the ECM for tissue 
engineering applications [58, 78].  Recently, electrospinning was introduced into the lab and 
research was conducted on the feasibility of in-house, consistent fabrication of electrospun 
scaffolds and results were promising.  This thesis aims to expand on those results to implement 
electrospun scaffolds into the BVM model.  For this reason, electrospinning will be reviewed and 
discussed in the following section.   
1.5 Electrospinning – An Overview 
Electrospinning is a fabrication technique investigated for the in-house production of 
polymer scaffolds as a replacement to ePTFE for the in vitro BVM system.  The following 
sections will discuss the history and theories behind electrospinning and how the system has 
been utilized to develop scaffolds for TEVGs.  Processing parameters of the system in relation to 
construct architecture and optimization of cell interaction will be discussed in detail.   
1.5.1 History of Electrospinning 
Electrospinning is the process of extruding a fine fiber from a charged polymer solution 
toward a grounded collector.  The fiber is continuously stretched by electric static forces and the 
evaporation of solvent while traveling through air prior to deposition [79].  The science and 
understanding behind electrospinning began with electrospraying over 100 years ago, in which 
polymer droplets, rather than fibers, were formed by electrostatic forces.  In 1934, Formhals 
patented the first device that successfully electrospun cellulose acetate into aligned small 
diameter fibers using an acetone solution [80].  Formhals continued to improve upon his work 
with additional patents over the next few years with minor, but effective changes, to the 
electrospinning setup [81, 82].  In 1969, Taylor developed a mathematical model to describe the 
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shape of a fluid droplet under an applied electric field.  The characteristic shape is called the 
Taylor cone.  Taylor determined the balance between surface tension and electrostatic forces, 
necessary for a successful jet formation, was achieved when the droplet cone angle was 98.6 
degrees [83].  In 1971, Baumgarten investigated solution processing parameters and the 
corresponding effects on fiber diameter [84].  Baumgarten determined increased solution 
viscosity lead to increased fiber diameters and as a result was able to create electrospun fibers 
from 500-1,100 nm. Since 2000, the number of publications on electrospinning has increased 
exponentially [79].  Not until the most recent work and accomplishments has the full potential of 
electrospinning been realized.  The ability to fabricate fibers with nano-sized diameters has 
become a promising reality for areas of filtration, membranes, wound dressings, drug delivery 
devices and tissue engineering scaffolds [78, 85].   
Fiber diameters of electrospun constructs have been achieved between several microns to 
just a few nanometers [86].  The high surface area per unit volume ratio achieved in electrospun 
nano-fibers can allow for enhanced cell proliferation, adhesion and differentiation in culture.  
Promising applications of electrospinning have been seen for several engineered tissues 
including vasculature [47, 48, 56, 63, 87], bone [41] and neural tissue [88].  The range of 
polymers that can be electrospun is only limited by the ability of the polymer to be brought into 
solution or melted.  Synthetic as well as natural polymers, such as collagen [89], elastin [56] and 
fibrinogen [90], have been successfully electrospun.  Drugs, antibodies, enzymes and 
natural/synthetic material complexes have also been incorporated into the electrospun constructs 
by including the substances in the polymer solution or by co-spinning [78, 91, 92].  Additionally, 
electrospun nano-fibers can be organized into a variety of architectures by manipulating 
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alignment and stacking of the fibers through various electrospinning protocols and setup 
modifications [93].  
1.5.2 Electrospinning Process 
Although simple to employ, the electrospinning process is a fairly complex system with 
multiple parameters that can be varied for construct and fiber optimization for a given 
application.  The general electrospinning setup consists of a charged polymer solution or melt, a 
capillary though which the polymer is forced, a pump, a grounded collector or target, and a high 
voltage supply (Figure 7).   
 
Figure 7 - A schematic representation of a typical electrospinning setup.  The setup consists 
of a high-voltage power supply, a polymer solution and a grounded collector.   
 
The polymer solution is composed of a dissolved polymer in a volatile solvent.  The role 
of the solvent is to adequately bring the polymer resin into solution and evaporate quickly when 
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exposed to air.  Evaporation of the solvent is necessary for the production of a mostly solid fiber 
upon collection.  The pump holds a reservoir, generally a syringe, containing the polymer 
solution and is responsible for regulating the flow rate of the solution.  The high voltage source 
generally outputs voltage from 8-30 kV.  An electrode from a high voltage source is applied to 
the solution usually by placing the electrode directly on the metal capillary or syringe needle.  
Depending on the application, various collectors can be implemented to acquire different shaped 
scaffolds such as a wire mesh, a flat plate, a fluid bath or a rotating plate around which the 
polymer wraps itself [56].  Stationary collectors are used to achieve randomly oriented fiber 
meshes where as rotating collectors can achieve varying degrees of fiber alignment depending on 
the speed at which the collector rotates.  For the purpose of tissue engineering blood vessels, a 
mandrel or rod which both rotates and translates back and forth can be used to fabricate tubular 
scaffolds of a specified length, uniform thickness, as well as diameter.  The distance, 
perpendicular to the collector, between the needle tip and the ground, is called the gap distance.  
The separation between the charged polymer solution and the grounded collector creates a static 
electric field. 
When a high voltage is applied to the metal capillary, the fluid droplet at the tip 
experiences both electrostatic repulsion between surface charges and Columbic forces exerted by 
the electric field [79].  As the charge increases, the droplet changes from a spherical shape to the 
Taylor cone.  As the charge separation between the solution and the collector overcomes the 
surface tension of the droplet, a thin polymer jet accelerates from the Taylor cone towards the 
collector.  A whipping instability transpires as the jet travels through the air, causing the jet to 
progress in a zigzag or conical pattern, which further thins the fiber diameter as the solvent 
evaporates before final deposition on the collector.  An extensive mathematical model of this 
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dynamic jet instability has explained the whipping instability to be a result of repulsive 
interactions between the jet and the external electric field [94].   
1.5.3 Optimization of Processing Parameters 
Several electrospinning processing parameters can be adjusted and possibly optimized in 
order to fabricate ECM mimicking scaffolds for TEVG development.  Parameters include 
solution parameters (e.g. viscosity, conductivity, solvent volatility etc.), operational parameters 
(e.g. gap distance, flow rate, electrical field strength) and environment (e.g. temperature, 
humidity etc.) [91, 95].  However, success is not limited to the alteration of a single parameter, 
but often a combination of several dependently operating parameters will be necessary to achieve 
continuous, small diameter fiber morphologies.  Several studies have been conducted on the 
interconnectivity of processing parameters and construct morphology.  The following sub-
sections will outline the major known contributors to electrospinning construct endpoints and 
variations of morphological characteristics, including the effect those construct outcomes have 
on cellular function for tissue engineering vascular grafts.   
1.5.3.1 Applied Voltage 
Small changes in the applied voltage can lead to large changes in fiber morphology.  
Applied voltage will initiate as well as destroy polymer jet formations.  Deitzel et al. studied the 
effects of voltage on fiber morphology and bead defects in electrospun polyethylene oxide 
(PEO)/water solutions (bead defects are essentially globs of polymer that form along the length 
of the fibers).  The study determined that increasing voltage changed the shape of the Taylor 
cone at the tip of the capillary, which in turn increased jet instability and the formation of bead 
defects.  Increasing the voltage even further led to the disappearance of the droplet at the 
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capillary tip and the jet would then be pulled from within the capillary [85].  In other words, the 
electric field strength is removing the polymer from the reservoir faster than the pump is feeding 
polymer into the capillary, thus eliminating the droplet and Taylor cone formation necessary for 
an electrospun construct.  This was confirmed by Zong et al. [96].  Another study on the effects 
of applied voltage on droplet and jet formation confirmed jet stability occurs when the average 
flow rate to the tip of the needle was matched by an equivalent flow rate at which the fluid was 
carried away by the jet [91].  The same study showed that when the voltage was too low, the 
droplet size increased and the gravitational forces overcame the field and pulled the droplet to 
the floor [91].  Buchko et al. showed an increase in applied voltage not only increases the field 
strength, creating smaller fiber diameters due to greater electrostatic stresses, but also draws 
more polymer solution from the syringe tip or capillary [97].  Consistent with Buchko, another 
group also noticed a decrease in fiber diameter as a result of increased applied voltage for a 5 
wt% solution of poly(L-lactide -co-ε-caprolactone) [P(LLA-CL)] with all other variables 
constant [98].  In summary, a high voltage supply (1-30 kV) is necessary to overcome the surface 
tension of the polymer solution, thus initiating the formation of a jet into a single continuous 
fiber.  Moreover, electric field strength contributes to the final fiber diameter of an electrospun 
construct, but must nevertheless be in balance with the feed rate of the solution.  However, 
studies have shown that applied voltage has a less significant effect on fiber diameter than 
solution viscosity [91, 98].   
1.5.3.2 Solution Viscosity 
There is a significant correlation between solution viscosity and fiber diameter; fiber 
diameter increases with increased concentration of polymer solution.  Adjusting solution 
viscosity is likely the most effective method of altering fiber diameter during electrospinning and 
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several studies have shown a linear relation between the two [85, 98-101].  Solution 
concentration inversely alters the surface tension of the liquid.  Decreasing surface tension 
reduces the number of bead defects present along fibers.  When increasing solution viscosity, 
beads become larger and more elongated while the average distance between the beads becomes 
greater until bead-less fibers are formed [102].  This removal of beads is subsequently 
accommodated by an increase in fiber diameter.   
When the solution concentration and viscosity is lowered to unstable levels, the 
electrospinning process transitions from a fiber forming jet to electrospraying, where capillary 
instability is driven by a high surface tension [102].  Demir et al., determined lower and upper 
concentration boundaries at 3.8 wt% and 12.8 wt%, respectively, for solutions of 
polyurethanurea in dimethylformamide (DMF).  At 3.8 wt% solution concentration, surface 
tension dominated the electric field strength and electrospraying was observed.  Above 12.8 wt% 
solution no jet was formed.  Further analysis of solution concentrations between 3.8 wt% and 
12.8 wt% showed bead defects occurring at the lower concentrations and curled fibers at higher 
concentrations, both of which decrease the much desired surface area to volume ratio for TEVG 
scaffold morphology [101].  The combination of high electric field strength with low solution 
concentrations can lead to multiple jet formations from the droplet at the tip of the capillary.  
Demir et al. observed this behavior, as a result, greater distribution of fibers formed on and 
around the collector [101].  Deitzel et al. studied the effects of solution concentration on fiber 
morphology and determined that low concentrations of solution had large variations in fiber 
diameters and the presence of fiber bundles, most likely a result of un-evaporated solvent upon 
collection.  At higher concentrations, fibers showed consistent uniformity in diameter with few 
fiber bundles [85].   
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In summary a critical range for polymer concentration exists for the electrospinning setup 
to function appropriately and to achieve a desired fiber diameter.  It is important to note that 
every polymer and solvent solution will have a different critical range due to differences in 
solvent and polymer characteristic properties, including; density, volatility (boiling point), 
viscosity, surface tension, and conductivity.  
1.5.3.3 Solvent Selection 
The main criteria for selecting solvents are to ensure the solvent is capable of bringing 
the working polymer into solution and to be volatile enough to dissolve rapidly when exposed to 
conventional atmospheric environments.  Other roles of the solvent include controlling surface 
tension, electrical conductivity, and viscosity of the solution [93].  If the polymer solvent 
solution cannot adequately carry an electrical charge, ionic surfactants can be incorporated into 
the solution.  The use of cationic surfactants, such as tetrabutylammonium (TBAC) or 
dodecyltrimethylammonium bromide (DTAB), has been shown to successfully increase the 
conductivity of the solution leading to the creation of continuous small fiber diameters [93, 103].  
Also, one study has demonstrated increased volatility leads to increased porosity and surface area 
in electrospun constructs compared to lesser volatile solvents [104].      
1.5.3.4 Flow Rate 
Fiber diameter increases with increasing flow rate and bead formations occur when the 
flow rate is too high [78].  The importance of flow rate, as depicted by Taylor, is to force 
polymer solution through the capillary at the same rate the solution is being carried away.  Such 
balance between flow-in and flow-out is necessary to maintain continuous, unbroken fiber 
formations [83].  If the flow rate is too high, the polymer solution will be forced out faster than 
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the jet can carry it away, increasing the droplet size at the tip of the capillary to unstable 
proportions and initiating bead formations along the length of the fibers.  Eventually as the 
droplet grows larger, gravity over takes the droplet and brings it to the ground.  Consequently the 
once continuous fiber will be broken and a new fiber will begin.       
1.5.3.5 Gap Distance 
The distance between the capillary or needle tip and the grounded collector is called the 
gap distance.  Gap distance is known to affect the outcome of fiber size however, these effects 
are minimal.  Fiber diameters decrease with increasing distance from the Taylor cone by 1-2 
orders of magnitude [78, 105].  As mentioned previously, as the fluid jet travels towards the 
collector, the jet undergoes a whipping instability.  This instability is necessary for the thinning 
of jet fiber diameter and the evaporation of solvent.  When the gap distance is too short, there is 
inadequate distance and time for the solvent to evaporate and the polymer will collect on the 
target in a wet state [89].  Megelski et al. noticed the aforementioned trend when studying 
electrospun polystyrene fibers and noticed increased bead formations with decreased gap 
distance as a result of residual solvent in the collected polymer [104].  Consequently the increase 
in gap distance allows for adequate time for solvent evaporation and increases the traveling 
distance for whipping instability to further thin the fiber.  There is, however, a critical distance at 
which the gap is too large and the electric field strength will no longer be able to overcome the 
surface tension of the liquid and the polymer will not collect on the target. 
1.5.3.6 Needle Size 
The effect of needle size on fiber morphology during electrospinning has been minimally 
investigated.  The basic function of the needle is to support an electrode to charge the polymer 
 30 
 
solution.  The needle also acts as a narrow exit point for the solution to be drawn through.  The 
main requirement of the needle is to not prohibit solution flow.  Mo et al. electrospun P(LLA-
CL) using 18G, 21G, 22G, and 27G needles.  Clogging and beading was observed with all needle 
sizes except the 27G needle (0.4 mm diameter).  However, the researchers argued that bead free 
fibers and no clogging could be easily obtained through increasing the solution concentration for 
larger diameter needles [98].  There is however, no conclusive study that suggests a smaller 
needle size can improve fiber quality or decrease fiber diameters.  There is no apparent gold 
standard for needle size in electrospun constructs from primary literature.  
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1.5.3.7 Fiber Diameters and Porosity 
Bio-mimicking the fibrous ECM to produce nanometer fiber diameters enhances vascular 
endothelial and smooth muscle cell adhesion and proliferation in scaffolds, with fiber diameters 
in the range of 50-500 nm [61, 62, 106].  These small fiber diameters allow for cells to contact 
multiple surfaces at one time.  The hypothesis has been proposed that proper cell phenotype will 
not be adequately achieved if the tissue engineered scaffold has fiber diameters equal to or 
greater than the cell diameters [107].  The main electrospinning operational parameters affecting 
fiber diameter are solution viscosity, applied voltage and the solution flow rate.  Generally, fiber 
diameters increase with increasing viscosity, decreasing electric field strength and increasing 
flow rate.       
Control of pore size and porosity is an attractive feature of electrospinning and is critical 
to proper cellular adhesion, proliferation, differentiation, and nutrient transport [60, 63-65].  The 
suggested optimal pore size for cellular infiltration is a minimum of 10 µm [108].  Much of the 
excitement over electrospinning has focused on the ability to produce nano-fibers, with little 
attention to porosity.  Although the nano-fibrous structure produced by electrospinning closely 
mimics the native ECM, the spatial characteristics associated with nano-fibers and the 
subsequent porosity do not reflect that of the ECM [95, 109].  Eichhorn et al. presented a 
theoretical, mathematical model to conclude that fiber diameter is directly related to pore size in 
electrospun constructs with cell penetration increasing proportionally with increasing fiber 
diameter [110]. Since pore size decreases with decreasing fiber diameters, what appears to be 
ideal fibers may lead to inadequate cellular infiltration for a 3D tissue engineered construct, due 
to pore sizes smaller than that of the cells they interact with [87].  Balguid et al. systematically 
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investigated the optimization of cell penetration by tailoring fiber diameters of electrospun 
poly(ε-caprolactone) (PCL) with fiber diameters ranging from 3.4-12.1 µm by adjusting solution 
concentration, applied voltage and flow rate.  Scaffolds were seeded with human venous 
myofibroblasts for 4 weeks.  A gradual increase in cell infiltration was observed with increasing 
fiber diameter and unobstructed penetration was only observed in the largest fiber diameter 
scaffold (12.1 µm).  PCL constructs showed homogenous tissue formation thus concluding the 
importance of fiber diameters in cellular delivery in electrospun scaffolds [87].  The study was in 
agreement with Eichhorns theoretical model that nano-fiber scaffolds are only beneficial as long 
as they are cell specific [87].  Others have shown the same results [111].  The concern associated 
with cellular infiltration does not necessarily apply to the BVM system.  The BVM requires only 
an endothelium to test the response of an intimal lining to stent implantation.  Therefore, nano-
fibers, which can increase cellular adhesion, may still be the optimum choice for the BVM.     
1.5.3.8 Fiber Alignment 
Fiber alignment can be used to increase radial compliance of a TEVGs [58].  Fiber 
alignment has been attributed to the rotation speed and translation of the rotating mandrel with 
random fibrous mats produced near 100 RPM and aligned fibrous mats near or at 1000 RPM 
[100, 112].  According to Choi et al, the rotation speed of the mandrel does not influence fiber 
diameter [113].  However, Choi et al. demonstrated fiber orientation induced a corresponding 
cellular orientation but had no affect on phenotypic expression of the cells.  The effects of fiber 
alignment on mechanical properties such as elastic modulus and strain to failure were evaluated 
and significant differences were found between aligned, random and orthogonal fiber 
orientations with highest strengths achieved in longitudinally aligned fiber constructs [100].  
Aligned nano-fibrous electrospun P(LLA-CL) vascular scaffolds showed improved vascular 
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SMC adhesion, parallel organization and contractile phenotype compared to unaligned polymer 
constructs [114].  These aligned scaffolds also achieved tensile strengths similar to the native 
artery therefore suggesting aligned constructs could be ideal for TEVGs.  However, it seems no 
current preference as to fiber orientation given the successful tissue formations seen in both 
randomly oriented and aligned fibrous scaffolds [115]. 
1.5.3.9 Environment 
A well controlled environment may be required to maintain a reproducible operation and 
such factors as humidity may play an important role in construct morphology [104].  At this 
time, there is little to no published work on the effects of humidity and temperature on the 
electrospinning of TEVGs.   
In summary, electrospinning offers several advantages to scaffold development for tissue 
engineering vascular constructs.  The flexibility in set-up design and the ability to tailor fiber 
morphologies and porosity through processing parameter optimization allows for tissue and cell 
specific scaffold development.  Electrospinning offers a probable alternative to purchasing 
ePTFE scaffolds for the BVM design, potentially allowing for in-house scaffold production that 
is scalable, controlled, and economical.  
1.6 Summary and Aims of the Thesis 
Coronary artery disease is affecting thousands of Americans each day.  Advancements in 
stent designs and treatment modalities necessitate better preclinical testing with fast reliable 
results.  The feasibility of an in vitro blood vessel mimic (BVM), that employs tissue engineered 
blood vessels for intravascular device testing, has been demonstrated for bare metal stents.  The 
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current BVM model has several physiological and mechanical limitations, as well as scale up 
limitations.  Improving upon the current design could have a substantial impact on intravascular 
device evaluation.  Presently, the model utilizes the scaffolding material ePTFE, a 
biocompatible, non-degradable polymer commonly used in bypass grafting.  Disadvantages to 
using ePTFE are high cost, the dependency on ePTFE suppliers, and lack of appropriate 
mechanical properties.  An ideal tissue engineered scaffold should mimic the ECM in structure 
(porosity, pore size, etc.) and mechanical properties (elastic modulus, tensile strength, etc.) and 
be capable of supporting cell adhesion, differentiation, proliferation, communication and the 
transport of all nutrients and growth factors. 
The aim of this thesis is to determine an alternative scaffolding material that can be 
electrospun to improve upon the BVM model by eliminating some of the current scaffolding 
limitations.  In this investigation, fibrous polymer scaffolds produced in-house by 
electrospinning for implementation into the BVM model, were studied.  The application of 
electrospinning to the production of tissue engineered grafts is highly favorable due to the ability 
to create polymer scaffolds with micron to nano-sized fibers and high porosity, both of which 
have shown to induce endothelial cell proliferation and attachment [78].  This thesis is driven by 
the hypothesis that electrospun polymer scaffolds for tissue engineering blood vessels are able to 
provide the framework for endothelialization and subsequent intimal lining formation in vitro 
and will improve upon the scalability and cost effectiveness of the BVM model.  There were 3 
phases to investigating this hypothesis.  The initial phase was to determine a material appropriate 
for electrospinning scaffolds for our tissue engineered vessel constructs based on primary 
literature review and requirements of the BVM model.  The second phase was to determine and 
optimize a protocol for electrospinning the new material by evaluating different solvents, 
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solution concentrations, flow rates and applied voltages.  The last phase of this investigation was 
to evaluate endothelialized electrospun constructs cultured in a flow bioreactor to assess intimal 
cellular lining formation.  Cellular responses were evaluated using fluorescent microscopy, 
histology and SEM.   
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Chapter 2 - Polymer Selection 
2.1 Introduction 
In 1937, DuPont patented poly(tetrafluoroethylene) [PTFE] as Teflon and considered the 
material to be a suitable electrical insulator.  The first medical application of PTFE began almost 
30 years later for an artificial heart valve [116].  Then, in 1969, W.L Gore & Associates used a 
process of melting and extruding to produce a micro-porous non-woven version of PTFE, known 
as ePTFE or expanded poly(tetrafluoroethylene) (Figure 8).  The process begins with a pure 
PTFE powder mixed with a volatile lubricating agent, which is then formed into a sheet.  That 
sheet is then heated and expanded until the desired structure is reached at which point the 
microstructure is stabilized by an amorphous locking step [117].  The microstructure of ePTFE is 
characterized by solid nodes connected by thin fibers with an average internodal distance of 30 
µm.  Porosity is near 85%, but can vary based on processing parameters [116, 117].  Early 
studies of ePTFE for vascular grafts showed the micro-porous nature of the graft supported better 
tissue adhesion [116].  The micro-porous structure and electronegative surface are critical 
aspects in ePTFE’s ability to promote endothelialization and to minimize reaction to blood 
components, respectively.  Today, ePTFE is the gold standard for large diameter vascular 
prostheses in clinical practice.  However, ePTFE in small diameter sites has resulted in high rates 
of thrombosis within a few months in vivo [50, 118, 119].  Primarily, the cause of small caliber 
ePTFE graft failure is compliance mismatch leading to intimal hyperplasia. 
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Figure 8 – The scanning electron microscope image of ePTFE (634X) shows the fibril-nodal 
microstructure characteristic of the polymer.  The nodes (blue arrow) run parallel to the 
length of the tubing and perpendicular to the internodal fibers (red arrow). 
 
As mentioned previously, the goal of the BVM model is to develop a high-throughput, 
cost effective, reliable model that simulates in vivo conditions in vitro to test intravascular 
devices prior to animal testing.  The model uses tissue engineering techniques to create an 
intimal lining of endothelial cells on the lumen of an ePTFE scaffold.  Some advantages to using 
ePTFE for the BVM design are the extensive pre-clinical and clinical data on endothelialization 
of ePTFE, ability to autoclave or gas sterilize the material, good biocompatibility, non-
biodegradability, availability in the proper size and dimensions, and proper EC orientation 
encouraged through its unique microstructural characteristics.  However, the high cost, 
dependency on suppliers, and non-native mechanical properties of ePTFE, as well as the inability 
to tailor properties specifically for the BVM, suggests in-house fabrication of an alternative 
scaffold could improve upon the scalability and cost effectiveness of the BVM model.  Also, a 
material that has mechanical properties more similar to the native vessel would create a more 
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physiologically representative environment to improve EC response during culture in vitro, and 
the resulting responses due to device implantation.  Finally, producing scaffold tubing in-house 
will open up further areas of research into optimizing scaffold design for tissue engineering 
vascular constructs.   
Recently, electrospinning was introduced to the Cal Poly BVM lab and research was 
conducted on the feasibility of in-house, consistent fabrication of electrospun scaffolds.  Studies 
primarily used P(LLA-CL) to assess the system, and results were promising.  Those efforts were 
focused on manufacturing and implementing an electrospinning apparatus, and testing the ability 
to produce scaffolds with consistent morphologies and mechanical properties using the new 
technique.  However, the study did not investigate electrospun constructs specifically for the 
BVM model.  As an extension of those efforts, this thesis aims to develop electrospun polymer 
scaffolds for implementation into the BVM as a replacement material for ePTFE.  In order to 
pursue such a hypothesis, the first objective of this thesis was to determine a suitable polymer for 
electrospinning tubular scaffolds for the tissue engineered BVM constructs. 
2.2 Methods for Material Selection 
 Material selection of a polymer suitable for electrospinning BVM tubular scaffolds was 
conducted based on review of primary literature.  Key words used for literature search were the 
following: electrospinning, tissue engineering, vascular grafts, and blood vessels.  A table was 
created outlining the following criteria for each investigation:  polymer name, polymer 
description, polymer source or vendor, application, solvents used, solvent vendor, cells and 
source, cell supplier, cultivation method, sterilization method, advantages, disadvantages, results, 
and citation.  Preliminary material requirements for tissue engineering that guided material 
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selection were biocompatibility and biodegradability.  Both biodegradable and non-
biodegradable materials were considered as long as degradation rates could be controlled so that 
integrity of the construct would be maintained throughout the course of device testing.  
Specifically for the BVM model, the polymer cost must be reasonable ($10/cm of ePTFE) and 
in-house sterilization must be possible.  Only polymers that have been electrospun previously 
were considered. 
2.3 Results 
After extensive literature review, poly(DL-lactide-co-glycolide) [PLGA; 75:25; 
lactide:glycolide] was selected for the investigation of electrospun scaffolds for implementation 
into the BVM model.  The following tables outline information gathered during the examination 
of appropriate polymers for tissue engineering that have been electrospun for biomedical 
applications (I, Table II).  The table categories were selected based on the information that would 
be beneficial to material selection, as outlined in the methods section.  Name, source and vendors 
of polymers, solvents, and cells were included to aid future purchasing if necessary.  A 
description of electrospun construct application and the disadvantages and advantages of each 
investigation along with key results specifically related to the material were reported.  Key 
factors of interest were material properties and cellular responses to the electrospun constructs.  
The BVM model currently utilizes human umbilical vein ECs (HUVECs) for tissue 
development.  Therefore, evidence of appropriate HUVEC responses is desirable for material 
selection.  Mechanical properties similar to the native vessel, if achieved, were noted given that a 
more compliant material is desired compared to ePTFE.  Sterilization and cultivation methods 
were included to compare with available methods used for the BVM model.  Autoclaving and 
ethylene oxide (EtO) gas sterilization are both available at Cal Poly for use.  However, 
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autoclaving is more desirable since EtO is more expensive.  Lastly, cultivation methods or 
bioreactor conditions were included to compare responses to flow, pressure and shear stress.  The 
ideal BVM model will simulate physiological pulsatile flow and pressure conditions, with the 
expectations that such conditions will lead to appropriate cellular responses during cultivation 
and device implantation.  Although such conditions may provide appropriate physiological 
conditions, pressure and shear stress due to flow could have a damaging effect on the scaffold 
material.  Therefore materials investigated under physiological flow conditions resulting in good 
cellular responses are highly desirable.  
It is important to note that the literature review was not limited to investigations 
presented in the following tables, but the tables offer a summary of how electrospinning has been 
implemented with several different polymers both natural and synthetic for different 
applications.  Several abbreviations are used in the following tables.  Please see Appendix A for 
definitions of all abbreviations.
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Based on the resulting information gathered from primary literature, the most promising 
materials were poly(caprolactone) [PCL], poly(lactide-co-glycolide acid) [PLGA], polyurethane 
(PU), and collagen or elastin blends with PCL or PLGA.  The final selection of PLGA was 
determined based upon EC responses, controlled degradation, acceptable sterilization techniques, 
mechanical properties similar to the native vessel, low cost, and availability.  The following 
section will discuss the various polymers considered and additional details supporting the final 
material selection. 
2.4 Discussion 
One main criterion for material selection was to use a polymer that had previously been 
electrospun. Natural materials considered were collagen and elastin.  Both materials can be 
electrospun together or independently and are advantageous since they are completely biologic.  
However, these materials lack the necessary mechanical properties needed for the BVM.  Natural 
and synthetic matrices such as PCL/collagen, PLGA/collagen, and PLGA/collagen/elastin attain 
comparable mechanical properties to the native vessel with favorable EC and SMC responses.  
PCL /collagen showed promising results in vascular tissue development in a pulsatile perfusion 
bioreactor followed by implantation into a rabbit model.  The scaffold was stable one month after 
implantation [120].  However, electrospun PCL without collagen from another study showed a 
great degree of compliance mismatch [121].  PLGA was effectively co-spun with collagen and 
elastin to achieve better compliance and burst strength [56].  Electrospun PLGA with collagen 
alone, cultured in a pulsatile, perfusion bioreactor enhanced vascular EC attachment and 
retention of cell phenotype [128].  Unfortunately, the high cost of collagen and the more 
complicated networks could be restrictive to the BVM model in terms of cost and scalability.   
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PLGA without the addition of natural polymers showed excellent results for vascular 
tissue development using HUVECs [127].  Another PLGA study achieved > 90% porosity with 
nano-sized fiber diameters which consequently encouraged good fibroblast attachment [109].  
PCL and PLGA can be gas sterilized.  Other polymers studied for the potential in vascular tissue 
engineering were PDO and PGA.  Both polymers have fast degradation rates.  Non-
biodegradable polymers are preferred for the BVM model in order to maintain structural 
integrity during endothelialization and intravascular device evaluation.  Such fast degrading 
polymers would be inadequate for the design.  Non-biodegradable polyurethanes can achieve 
compliance similar to the native vessel [130], but polyurethanes are generally expensive, hard to 
find, and variable in composition.  However, if progress is made towards the addition of SMCs, 
in addition to ECs, a faster degrading polymer might be acceptable for the BVM model.  
Polymers with relatively slow degradation rates are possible as long as degradation does not 
affect the integrity of the construct before the end of device evaluation (~3-4 weeks). 
In conclusion, PLGA was determined to be the most acceptable and appropriate polymer 
for the investigation into electrospinning scaffolds for the BVM.  In summary, PLGA’s ability to 
be electrospun into fibrous, porous constructs, and its ability to elicit appropriate cellular 
responses under physiological pulsatile flow environments make the polymer suitable for 
vascular tissue engineering applications.  PLGA is a relatively inexpensive polymer that can be 
EtO gas sterilized in house.  PLGA’s compatibility for co-spinning with biologics, although not 
an objective of this thesis, could be beneficial for opening up other areas of research and design. 
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Chapter 3 - Electrospinning PLGA 
3.1 Introduction 
PLGA was determined to be the most appropriate polymer for the investigation of 
electrospun scaffolds for the BVM.  Additionally, PLGA is one of the most well studied 
synthetic polymers for tissue engineering of various tissue constructs [131-133].  The FDA has 
approved the use of PLGA in several biomedical applications due to good biocompatibility and 
controlled biodegradability [131, 132].  PLGA is a co-polymer of lactic and glycolic acid, and 
degradability can be tailored for targeted applications via the ratio of acid units.  Degradation of 
PLGA occurs by hydrolysis of the ester linkages in the presence of water producing by-products 
of lactic and glycolic acid, both of which are by-products of metabolic pathways under normal 
physiological conditions.  Degradation however is a concern for the BVM model.  The model 
necessitates scaffold structural stability to support an endothelium throughout the course of 
intravascular device evaluation.  In order to incorporate a biodegradable polymer into the BVM 
design, the degradation rate of the polymer must be sufficiently slow (3.4 weeks) to allow for 
complete device testing. 
In vitro and in vivo breakdown rates of electrospun PLGA scaffolds with mole fractions 
of 85:15, 75:25 and 50:50 were compared by Blackwood et al [134].  PLGA 85:15 had no 
significant change in vitro after 108 days.  PLGA 75:25 did not begin rapid degradation for 80 
days, whereas PLGA 50:50 underwent rapid degradation within 8 days.  In vivo subcutaneous 
implantation of electrospun PLGA scaffolds also confirmed the potential use of 85:15 and 75:25 
for tissue engineering.  The study noted good fibroblast growth, EC growth, and ECM 
production for 85:15 and 75:25 in vivo, with significant degradation after 3-4 months of 
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implantation [134].  From the results of Blackwood et al., it can be assumed that degradation of 
both PLGA 85:15 and PLGA 75:25 are slow enough to be used in the BVM model.  Also, 
incorporation of SMCs to act as the media of the vessel may necessitate such biodegrading 
polymers, in which case the scaffold no longer provides the long term structural support as a 
layer of smooth muscle is created.  In conclusion, PLGA 75:25 was selected for the remainder of 
this investigation.  Although both PLGA 85:15 and 75:25 are viable options, the 75:25 ratio has 
been used more extensively in literature.   
PLGA meets other BVM criteria listed in the objective of this investigation as outlined in 
Chapter 2.  The purpose of this chapter is to develop a protocol for electrospinning PLGA.  
Solvents, solution concentration, and processing parameters (flow rate and applied voltage) will 
be investigated for optimization of construct morphology and mechanical properties of the 
PLGA scaffolds.  Once a protocol is finalized, PLGA scaffolds will be developed at the final 
protocol for evaluation in the BVM bioreactor to test the ability to form a human endothelial cell 
lining.  
3.2 Methods 
3.2.1  Solvent Selection 
 Chloroform (CHCl3; 99.9%, extra dry, water < 50 ppm; mol wt. 119.38; Cat. No. 
AC32682-0010_Acros Organics No.: 326820010), tetrahydrofuran (THF; anhydrous > 99.9%, 
inhibitor free; Cat. No. 401757) and dimethylformamide (DMF; anhydrous, 99.8%; Cat. No. 
227056) were purchased from Fisher Scientific and Sigma-Aldrich Chemical Company.  
Poly(D,L-lactide-co-glycolide) [75:25; PLGA; mol wt. 66,000 - 107,000; Cat. No. P1941] was 
purchased from Sigma Life Sciences.  Chloroform, THF, and DMF were considered based on 
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primary literature to determine an appropriate solvent for electrospinning PLGA.  Comparisons 
were made based upon cost, volatility, and primary literature review on electrospinning.  In 
addition, 10 wt% and 15 wt% solutions of PLGA in THF and PLGA in CHCl3 were made 
according to the protocol in Appendix B.  All four solutions were electrospun according to the 
protocol in Appendix C.  The four spins were used as trial spins to monitor effectiveness of 
solvents to bring PLGA resin into solution and to visually evaluate the ability to electrospin each 
solution.  All spins were conducted with an 18 GA needle, and a gap distance of 25.4 cm.  
Mandrel rotation control was set to 6 and translation was set to 3.  Flow rate and applied voltages 
were varied during the spin process as each spin was solely observational and experimental.    
3.2.2 Solution Concentration 
Poly(D,L-lactide-co-glycolide) [75:25; PLGA; mol wt. 66,000 - 107,000; Cat. No. 
P1941] was purchased from Sigma Life Sciences.  Using the solvent determined appropriate for 
electrospinning PLGA in the previous section, an optimum weight percent solution concentration 
was investigated.  Solution concentration was varied between 10 wt% and 18 wt% PLGA in 
CHCl3.  Each solution was prepared according to the protocol provided in Appendix B.  
Calculations to determine grams of polymer necessary for a given wt% solution were conducted 
based on 4 ml solvent (See Appendix B).  Each solution was electrospun according to the 
protocol provided in Appendix C.  For each spin, 3 ml of solution was electrospun out of the 4 
ml solution made.  Mandrel rotation control was set to 6 and translation was set to 3.  Table III 
provides the specific solution and processing parameters set for each different wt% solution 
tested.  Flow rates and voltages were adjusted specifically based upon the response of droplet 
and jet formation at the start of the spin process.  This was necessary since at this time no 
protocol for electrospinning PLGA had been determined and each spin was experimental.  With 
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the completion of each spin, the scaffold was left on the mandrel in a desiccator for at least 24 
hours in order to eliminate any excess solvent prior to scaffold removal and analysis.  All applied 
voltages listed are approximations since no exact measurement system is in place for the 
electrospinning setup. 
  
Table III – Solution and Electrospinning Parameters for PLGA in Chloroform 
 Solution Parameters Electrospinning Parameters 
Spin 
Title 
wt% 
PLGA 
(g) 
CHCl3 
(ml) 
Gap Distance 
(cm) 
Needle 
(GA) 
Flow Rate 
(ml/hr) 
Applied 
Voltage (V) 
SPIN 1 10 0.653 4 25.4 18 Blunt 6.1 no data record 
SPIN 2 12 0.806 4 25.4 18 Blunt 2.5 10,500 
SPIN 3 13 0.888 4 25.4 18 Blunt 3 10,500 
SPIN 4 15 1.031 4 25.4 18 Blunt 5.5 no data record 
SPIN 5 18 1.201 4 25.4 18 Blunt 0.1 - 6.0 10 - 20,000 
  
3.2.2.1 Morphological Analysis 
Electrospun PLGA scaffolds, SPIN 1-5, were evaluated using scanning electron 
microscopy (SEM) for qualitative analysis of construct morphology.  Keeping the scaffold on the 
mandrel for support, each scaffold was cut into 3 sections (approximately 4 cm long each) with a 
scalpel, and sections were labeled A-B, B-C, and C-D (Figure 9).  One sample from each section, 
approximately 3 mm wide, was cut and taken off the mandrel.  First a sample from A-B was cut 
and removed, and then what was left of A-B was removed and placed on a glass stir rod.  This 
was repeated for all sections.  The glass stir rod with leftover sections was placed back in the 
desiccator and labeled appropriately with spin title, date and wt% concentration.  The 3 mm 
samples were then cut in half so both lumen and ablumen could be analyzed with the SEM.  
Samples were fixed to a SEM stage and sputter coated in gold for approximately 60 seconds 
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(Figure 9).  Qualitative analysis of electrospun PLGA construct morphologies was conducted 
using the SEM and several images were taken at various magnifications. 
 
Figure 9 – The above images are example images and do not display SPIN 1 – 5.  The left 
image shows polymer covering the mandrel after electrospinning.  The labeling method is 
shown.  The large SEM stage shows both lumen and ablumen samples sputter coated in 
gold (right).  All electrospun samples were prepared in this manner for SEM. 
 
3.2.3 Processing Parameter Optimization 
 After an optimum wt% concentration was determined, fine tuning of applied voltage and 
flow rate was conducted.  Poly(D,L-lactide-co-glycolide) [75:25; PLGA; mol wt. 66,000 – 
107,000; Cat. No. P1941] from Sigma Life Sciences and chloroform (CHCl3; 99.9%, extra dry, 
water <50 ppm; mol wt. 119.38; Cat. No. AC32682-0010_Acros Organics No.: 326820010) 
from Fisher Scientific were used for this experiment.  Four 15 wt % solutions of PLGA in CHCl3 
were prepared according to Appendix B.  Calculations to determine grams of polymer necessary 
for a given wt% solution were conducted based on 4 ml CHCl3.  Each solution was electrospun 
according to Appendix C.  Only 3 ml of the 4 ml solution was electrospun for each spin.  
Mandrel rotation was set to 6 and translation set to 3 for all spins.  Table IV provides the specific 
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processing parameter for each of the 4 spins.  Each applied voltage is an estimate since no exact 
measuring system is in place.  A temperature and humidity monitor was kept in the containment 
chamber and both were recorded at the beginning and end of each spin to monitor affects if any.  
Only temperature and humidity changes of ±5 units were considered serious to note, otherwise 
values displayed are an average from start to finish of each spin. 
 
Table IV – Electrospinning Process Parameters for 15 wt% PLGA in CHCl3 
 Solution 
Parameters 
Electrospinning Parameters 
Spin 
Title 
PLGA (g) 
Gap 
Distance 
(cm) 
Needle 
(GA) 
Flow Rate 
(ml/hr) 
Applied 
Voltage 
(V) 
Temperature 
(°F) 
Humidity 
(%) 
SPIN 6 1.036 25.4 18 Blunt 5.5 12,000 66.1 47 
SPIN 7 1.031 25.4 18 Blunt 3 12,000 69.0 40 
SPIN 8 1.047 25.4 18 Blunt 3 15,600 68.4 38 
SPIN 9 1.038 25.4 18 Blunt 5.5 15,600 68.2 37 
 
3.2.3.1 Fiber Diameter Measurements 
SEM was used to both qualitatively evaluate general construct morphology and 
quantitatively measure fiber diameter of the luminal surface of the scaffold.  SPIN 6-9 were 
prepared in the same manner as mentioned previously in section 3.2.2.1 for SEM analysis.  
Following that protocol, a total of 3 luminal and 3 abluminal samples were sectioned per spin.  
Both lumen and ablumen were observed for a general consistency using the SEM, however, the 
luminal surface was of greatest concern for fiber diameter measurements.  One corner of each 
lumen sample was selected to start image collection.  All images were acquired at a 
magnification of 2000X.  Images were acquired every 20 screens from the selected corner.  Five 
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images were taken per lumen sample per spin, for a total of 15 images per spin.  A program 
called ImageJ was used to measure fiber diameters from the SEM images (Figure 10).  The 
program converts number of pixels into a length scale.  Fiber diameters were measured 
according to the protocol in Appendix E.  Approximately 5 fiber diameter measurements were 
taken per image for a total of 75 measurements per spin.  Average fiber diameter and standard 
deviation were calculated in Excel. 
 
 
Figure 10 - ImageJ can be used to convert pixels into a length scale.  The above SEM image 
shows a fiber diameter of 6.334 microns reported by ImageJ output. 
 
322 pixels 
 54 
 
3.2.3.2 Mechanical Testing 
Mechanical properties of 15 wt% PLGA electrospun scaffolds were measured using a 
uniaxial tensile tester (Instron In-Spec 2200 Portable Tester with PDA Data Management 
Software) equipped with a 250 N (50 lb) load cell.  Section A-B, from SPIN 6-9, as described in 
section 3.2.2.1, were used for this test.  Each A-B section was cut for both longitudinal and 
circumferential tensile testing using a scalpel or scissors. Two samples were cut to be tested 
longitudinally and one sample was cut for circumferential testing as shown in the schematic 
illustration below (Figure 11).  Circumferential samples were cut once along the scaffold 
longitudinal axis and rolled out flat for testing. 
 
 
Figure 11 - Illustration of section A-B from each SPIN prepared for tensile testing.  Blue 
lines represent cutting lines.  2 samples were created for longitudinal testing (yellow and 
light gray) and one sample for circumferential testing (dark grey). 
 
 Each sample was loaded into the Instron test grips in the proper test direction.  Sample 
dimensions (gage length, width, and thickness) were measured using digital calipers.  The data 
acquisition system reported time, extension, and load.  Extension and load were converted to 
stress and strain in Excel.  The ultimate tensile strength and Young’s Modulus were obtained 
Circumferential 
test piece 
Longitudinal 
test piece 
Longitudinal 
test piece 
 55 
 
from the stress-strain curves.  Young’s modulus was calculated from the slope of the initial linear 
region of the stress strain curve. 
3.3 Results 
3.3.1 Solvent Selection 
Chloroform was determined an acceptable solvent for electrospinning PLGA for the 
remainder of this investigation.  Reasons for selecting chloroform are cost, adequate volatility, 
and the ability to bring PLGA resin into solution.  DMF was considered because it is often used 
in combination with THF or chloroform [78, 133, 135].  Boiling points for THF and chloroform 
are 60.5-61.5 ºC and 65-67 ºC respectively, making both equally viable options with THF being 
slightly more volatile.  Chloroform is approximately $12.00-20.00 cheaper than both THF and 
DMF and has been used extensively in literature for electrospinning various polymers [78, 87, 
136, 137].  A price comparison table is shown below. 
 
Table V - Price Comparisons for Different Solvents 
 100 ml 1Liter 
Chloroform $25.50 $52.10 
THF $38.30 $79.80 
DMF $37.60 $73.30 
*Prices obtained from Sigma-Aldrich and Fisher Science 
  
Both THF and CHCl3 effectively brought PLGA resin into solution according to the 
protocol in Appendix B.  Electrospinning of 10 wt% PLGA in THF was unsuccessful and no 
scaffold construct was formed.  Electrospun 15 wt% PLGA in THF resulted in electrospraying.  
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Both 10 and 15 wt% solutions of PLGA in CHCl3 were successfully electrospun with polymer 
collection evident on the mandrel.   
3.3.2 Solution Concentration 
This section is provided to give a record of observations seen during and at the end of 
SPIN 1-5.  Given this was one of the first experimental investigations using the electrospinning 
device, several observations and errors were recorded and explanations of observations are 
included in the discussion section of this chapter.   
SPIN 1:  At the start of SPIN 1, 10 wt% PLGA, the mandrel and rotator cuff was not 
working when the rotor was turned on.  By tapping the rotator cuff, mandrel rotation was 
initiated and the rotator cuff unstuck.  During the spin, a large droplet of polymer solution 
formed at the tip of the capillary.  Droplet size would reach an unstable size and fall to the floor.  
Also, multiple fiber jets were coming from the droplet.  Usually excess fiber jets scattered about 
the collector and dried separate from the mandrel.  The voltage at which the spin was conducted 
was not recorded, however the process was most likely conducted between 10,000 and 20,000 V.  
Also, the lab did not have access to a desiccator until SPIN 2 and the scaffold was kept in a 
plastic zip lock bag until further analysis. 
SPIN 2:  The flow rate was reduced for SPIN 2, 12 wt% PLGA, to 2.5 ml/hr in order to 
possibly reduce the amount of polymer lost to a high flow rate as observed during SPIN 1.  With 
the start of the electrospinning process, the mandrel was quickly coated with the polymer and a 
stable jet formed from the tip of the needle.  However, an additional jet formed that solidified 
onto the ceiling of the containment chamber. 
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SPIN 3:  Since SPIN 3, 13 wt% PLGA, was slightly higher in concentration than SPIN 2, 
a similar flow rate was maintained (3 ml/hr).  Again, polymer collection on the mandrel was 
immediately evident as in SPIN 2.  Not long into the spin, the polymer droplet began to grow 
larger and hang from the tip of the capillary. The droplet was elongated in shape, however, a 
stable jet continued from the tip of the elongated droplet.  When the droplet grew too large, it 
would fall to floor of the containment chamber and a new jet would initiate.   
SPIN 4:  For SPIN 4, 15wt% PLGA, a flow rate of 5.5 ml/hr was attempted in order to 
spin a full scaffold in less amount of time.  No voltage was recorded for this spin.  However, it 
was recorded that increasing the voltage led to multiple jet formations.  The voltage was then 
decreased until a stable jet was observed.     
SPIN 5:  The SPIN at 18 wt% PLGA was conducted as a troubleshooting experiment, as 
well as to see the affects of solution concentration on construct morphology.  Flow rate was 
varied between 0.1 ml/hr and 6.0 ml/hr and voltage varied between 10,000-20,000 V.  The 
purpose of the variation was to see if any observable increase in droplet stability could be 
reached by changing the flow rate and voltage parameters.  Flow rate was started at 6.0 ml/hr and 
the voltage was adjusted.  When the voltage was too high, multiple jets formed from the droplet 
and or the droplet became concave inward and circular with multiple jets forming around the 
outer diameter.  If the voltage was too low, a jet would cease to form and polymer solution 
would drip from the tip of the capillary.  When voltage seemed to stabilize the jet formation, a 
large droplet began to form.  The flow rate was reduced slowly until 0.1 ml/hr to see if any 
significant difference in droplet size was evident.  The droplet size did decrease with reduced 
flow rate, but remained throughout the entire spin. 
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3.3.2.1 Morphological Analysis 
Morphological examination using SEM images of SPIN 1, 2, 3, 4 and 5 are shown below 
in Figures 13-20.  At 10, 12 and 13 wt% PLGA, fiber morphologies contained rounded and 
elongated bead defects interconnected with nano-sized fiber diameters (Figure 12,Figure 
13Figure 14,Figure 15).  SPIN 4 and 5, at 15 and 18 wt% PLGA respectively, had continuous 
un-beaded fiber networks with fiber diameters of just a few microns (Figure 16Figure 17, Figure 
18, Figure 19).  Figure 20 shows the continuity of the electrospun fibers however, there appears 
to be no preferential direction of the fibers.  Note images were taken at different magnifications.  
Based on SEM analysis, the optimum solution concentration for the continuation of this study 
was 15 wt% PLGA in CHCl3.   
It should be noted that SPIN 1 was difficult to detach from the mandrel and parts of the 
scaffold were damaged in the process.  Unlike SPIN 1, SPIN 2, 3, 4 and 5 were maintained in a 
desiccator until removal from the mandrel.  The use of desiccant allowed for easier removal of 
polymer from the mandrel by drying excess solvent.  There was a noticeable increase in stiffness 
for all scaffolds maintained in the desiccator. 
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Figure 12 - SEM image of SPIN 1, 10 wt% 
PLGA, electrospun construct showing 
globular bead defects amongst small fibers 
(677X).
 
 
Figure 13- SEM image of SPIN 1, 10 wt% 
PGLA, electrospun construct with 
elongated bead defects among small fibers 
(784X).
 
Figure 14 - SEM image of SPIN 2, 12 
wt% PLGA, electrospun construct with 
elongated beads on fibers (615X).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 -SEM image of SPIN 3, 13 wt% 
PLGA, electrospun construct with few 
elongated beads and varying fiber sizes 
(821X). 
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Figure 16 – SEM image of SPIN 4, 15 
wt% PLGA, electrospun construct with 
continuous fiber network (669X). 
 
 
Figure 17 – SEM image of SPIN 4, 15 
wt% PLGA, electrospun construct with 
continuous fibers (1543X). 
 
 
Figure 18 - SEM image of SPIN 5, 18wt% 
PLGA, electrospun construct with 
continuous fibers (1482X). 
 
 
 
 
 
Figure 19 - SEM image of SPIN 5, 18 
wt% PLGA, electrospun constructs with 
continuous fibers (68X) 
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3.3.3 Processing Parameter Optimization 
 The purpose of this section is to report any observations or error that occurred during the 
electrospinning of SPIN 6, 7, 8 and 9.  Again, this is the second run of trial spins investigated 
and it was therefore important to record any interesting observations, as well as reasons for 
parameter adjustments.  Results of each spin are presented below and will be further discussed in 
the discussion section of this chapter. 
SPIN 6:  At the beginning of SPIN 6 the temperature and humidity were recorded to 
monitor effects, if any.  This was not considered for SPIN 1-5 and no environment data exists for 
those spins.  Polymer coating of the mandrel began immediately at the start of the 
electrospinning process for SPIN 6.  An extruded droplet formed at the tip of the capillary; 
however a stable jet was formed at the tip of the droplet.  After 1 ml of solution was spun, the 
process was stopped and restarted with a flow rate of 3.5 ml/hr and voltage was maintained at 
12,000 V.  At the slower flow rate there was no difference in droplet size formation.  Due to that 
fact, the flow rate was returned to 5.5 ml/hr for the remainder of the spin. 
 SPIN 7:  Parameters for SPIN 7 were set to 3 ml/hr and 12,000 V.  Parameters remained 
constant throughout the entire spin process.  Even with a lower flow rate, similar polymer build 
up, as in SPIN 6, was observed. 
 SPIN 8:  The purpose of SPIN 8 was to test a lower flow rate (3 ml/hr) with an increase 
in voltage.  Voltage began at 12,600 V but was soon amped up to 18,000 V.  In both cases the jet 
was unstable; however a decrease in voltage to 15,600 V produced a stable jet formation. 
 62 
 
 SPIN 9:  The purpose of SPIN 9 was to test a higher flow rate (5.5 ml/hr) with the 
voltage found to stabilize the jet during SPIN 8 (15,600 V).  All parameters were kept constant 
the entire spin. 
 For each spin, humidity and temperature were recorded.  Humidity was highest for SPIN 
6 at 47%.  When observing the collected polymer on the mandrel at the end of SPIN 6, the 
collected polymer appeared wet or wavier than what has previously and afterwards been 
observed.  This suggests minor changes in humidity may play a role in complete solvent 
evaporation during the electrospinning process.    
3.3.3.1 Fiber Diameter Measurements 
SPIN 6, 7, and 8 were difficult to remove from the mandrel during SEM sample 
preparation.  This could be due to excessive use of the original mandrel.  Also, using a scalpel to 
cut samples off the mandrel leaves grooves in the mandrel surface.  These grooves could act as 
areas for polymer to become wedged making removal more difficult.  SPIN 9 was electrospun 
onto a new mandrel made in-house (See Appendix D).  The scaffold came off with no difficulty 
and was possibly the easiest scaffold to remove thus far.  New mandrel designs were wet 
polished in methanol.  Smooth surfaces achieved from this process could have aided in scaffold 
removal.  New mandrels will be used for all future spins. 
SEM images of SPIN 6-9 are shown below in Figures 21-28.  Images showing both 
lumen and ablumen morphologies are displayed.  Results of fiber diameter measurements are 
listed in Table VI.  SPIN 6 achieved the smallest average fiber diameter of 5.49 microns.  SPIN 8 
achieved the largest average fiber diameter of 7.35 microns.  Raw data collected for all fiber 
diameter measurements is included in Appendix F.  It is important to note, the method of fiber 
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diameter measurements is not entirely accurate due to apparent verses true fiber diameter.  Small 
fibers may change more in their spatial orientation.  Meaning, a fiber that appears straight in a 
SEM image may actually be turning into or out of the page.  For this reason average measured 
fiber diameter is potentially greater than the actual average diameter of each electrospun 
construct being observed.  This possibility was not accounted for in the statistical analysis and 
data collection, and is assumed an insignificant effect. 
 
Table VI - Fiber Diameter Results for 15 wt% PLGA Electrospun Scaffolds 
 
Fiber Diameter 
(um) 
Standard 
Deviation 
Electrospinning Parameters 
Spin Title 
Flow Rate 
(ml/hr) 
Applied Voltage 
(V) 
SPIN 6 5.49 0.93 5.5 12,000 
SPIN 7 5.85 0.64 3.0 12,000 
SPIN 8 7.35 1.00 3.0 15,600 
SPIN 9 6.11 0.75 5.5 15,600 
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Figure 20 - SEM image of SPIN 6, lumen 
of PLGA electrospun construct (2000X). 
 
Figure 21 - SEM image of SPIN 6, 
albumen of PLGA electrospun construct 
(610X). 
 
 
Figure 22 - SEM image of SPIN 7, lumen 
of PLGA electrospun construct (2000X). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 - SEM image of SPIN 7, 
ablumen of PLGA electrospun construct 
(800X). 
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Figure 24 - SEM image of SPIN 8, lumen 
of PLGA electrospun construct (2000X).
 
Figure 25 - SEM image of SPIN 8, 
ablumen of PLGA electrospun construct 
(800X). 
 
 
Figure 26 - SEM image of SPIN 9, lumen 
of PLGA electrospun construct (2000X).
 
Figure 27 - SEM image of SPIN 9, 
ablumen of PLGA electrospun construct 
(800X). 
.
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3.3.3.2 Mechanical Testing 
 Tensile properties of electrospun 15 wt% PLGA scaffolds prepared with different 
processing parameters are provided in Table VII.  Stress strain plots and Young’s modulus plots 
for all spins can be found in Appendix G. 
 
Table VII - Mechanical Properties of 15 wt% PLGA 
 Ultimate Tensile Strength Young’s Modulus 
Spin 
Title 
Circumferential 
Longitudinal 
Set 1 
Longitudinal 
Set 2 
Circumferential 
Longitudinal 
Set 1 
Longitudinal 
Set 2 
SPIN 6 4.29 MPa 3.37 MPa  3.23 MPa 39.4 MPa 82.9 MPa 114.6 MPa 
SPIN 7 4.89 MPa 5.27 MPa NA 11.8 MPa NA NA 
SPIN 8 4.18 MPa 5.37 MPa 5.31 MPa 37.1 MPa 100.8 MPa 126.0 MPa 
SPIN 9 3.60 MPa 4.13 MPa 3.13 MPa 37.6 MPa 130.1 MPa 111.6 MPa 
 
Missing data for SPIN 7 was due to operator error when the data acquisition system was 
exited before properly saving the data.  Tensile strength and ultimate tensile strength for all 
spins, in both the longitudinal and radial directions, is within range for the native vessel 
(approximately 1.40 - 11.14 MPa [58]).  Young’s modulus for the human blood vessel has been 
reported at 1-3 MPa, however collagen alone has been reported to have a Young’s modulus of 
approximately 45 MPa [138].  Circumferential Young’s modulus for all spins ranged from 37-39 
MPa except for SPIN 7 in which case some data was lost and the results are skewed.  
Longitudinal ultimate tensile strength (UTS) and Young’s modulus were higher than the 
circumferential values for all spins except for SPIN 6 whose radial UTS was greater than the 
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longitudinal UTS.  There were no observable trends between mechanical properties and fiber 
diameter, although an increase in stiffness with increased fiber diameter would be a logical 
conclusion.  However, given the relatively small range of fiber diameters achieved for SPIN 6-9, 
it is reasonable that no trend would be apparent. 
It is important to note that a common failure location of tensile test samples was at the 
test grips.  This is expected due to the rectangular shape of the sample pieces.  Also, deformation 
of samples is possible due to cutting and flattening of the pieces during sample preparation and 
loading into the Instron tester.  This is especially true for radial samples where more deformation 
is necessary to load the sample properly. 
3.4 Discussion 
3.4.1 Solvent Selection 
The importance of the solvent is to adequately bring the polymer resin into solution and 
to evaporate quickly when exposed to air during the electrospinning process.  Evaporation of the 
solvent is necessary for the thinning of the fiber jet and the production of a mostly solid fiber 
upon collection.  For this reason both THF and CHCl3, two highly volatile solvents, were 
considered.  DMF was considered as it is often used in combination with THF and CHCl3.  
Although THF is slightly more volatile than CHCl3, the cost for THF compared to CHCl3 was 
much greater.  An important aspect of the BVM model is cost effectiveness and scalability; 
therefore chloroform would be the optimum choice due to cost savings of $15.00-20.00 
compared to THF.  For this reason DMF was disregarded as well, since chloroform has proven to 
be capable of producing electrospun constructs without the additional solvent in primary 
literature.  This too will keep the cost low.  In early experimental trials comparing electrospun 
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PLGA in both THF and CHCl3, solutions of CHCl3 were the first to be successfully electrospun. 
This was due to greater viscosity of CHCl3 solutions compared to THF solutions of the same 
wt% in PLGA.  In conclusion, trial experiments showed no significant benefit for one solvent 
compared to the other; however, the early success with CHCl3 was promising. Selection of 
CHCl3 came down to the fact that previous work on the feasibility of electrospinning scaffolds 
for the BVM lab used CHCl3 for electrospinning P(LLA-CL) solutions.  This previous 
experience will be beneficial for comparison of electrospun constructs and troubleshooting as 
necessary.  Future work could pursue chloroform combinations with DMF as often done in 
literature.  Investigations would need to be conducted on the benefits to such combination verses 
no combination.  In conclusion, CHCl3 is an acceptable solvent, based on cost, previous use, and 
volatility, to use for the investigation of electrospinning PLGA for the BVM. 
3.4.2 Solution Concentration 
The large droplet formation at the tip of the needle observed during SPIN 1 could be due 
to high flow rate (6.1 ml/hr) combined with a low solution concentration and/or a low voltage.  
However, multiple fiber jet formations coming from the large droplet would be indicative of a 
voltage that was too high.  A disadvantage to the process was primarily the loss of polymer 
associated with polymer solution accumulating on the tip of the capillary.  When the large 
droplet becomes unstable and falls from the capillary, the continuous fiber jet breaks which 
could potentially cause a layering effect where each new jet forms a sheet over the previous 
collected jet.  However, this layering effect hypothesis was not investigated.  SPIN 2 was more 
successful with a decrease in flow rate to 2.5 ml/hr and an increased solution concentration 
compared to SPIN 1.  A mostly stable jet was formed for SPIN 2; however one fiber formed 
towards the ceiling.  This could be due to residual charge or polymer in the containment chamber 
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that was not removed prior to the beginning of the spin process.  During SPIN 3, flow rate was 
slightly increased (3 ml/hr) from SPIN 2.  A successful jet was formed, however, the droplet 
elongated until it fell to the floor of the containment chamber.  Although the jet formation 
appeared optimum and no additional jets formed, the wasted polymer during the spin is still a 
disadvantage.  Again, polymer build up suggests a flow rate that is too high.  However, adjusting 
flow rates during both SPIN 4 and SPIN 5 led to accumulation of polymer on the needle tip 
regardless of the flow rate with a slower accumulation evident with slower flow rates and faster 
accumulation at higher flow rates.  Ruling out flow rate and applied voltage, solution viscosity is 
the only factor remaining that may be the primary source of large droplet accumulation.  
 Solution concentration is the most effective method of altering fiber diameter during 
electrospinning [85].  The high surface area per unit volume ratio achieved in electrospun micron 
and nano-fiber constructs can allow for enhanced cell proliferation, adhesion, and differentiation 
in culture.  Since solution concentration is the dominate parameter leading to construct 
morphology, a solution concentration that is capable of producing continuous, non beaded fiber 
networks was  the first step to building an electrospinning protocol for this thesis.  From the 
results of this study, 15 wt% PLGA in CHCl3 (SPIN 4) solutions were determined optimum.  
This was the lowest concentration of PLGA in CHCl3 that led to continuous non-beaded fiber 
networks.  Higher viscosity is known to favor the formation of non-beaded networks as also 
evident from the results of this study, as well as reports in literature [102].  Surface tension 
favors the formation of beads and reduced surface tension favors no beads.  As mentioned 
previously, solution concentration inversely affects surface tension and therefore an increase in 
solution concentration should produce less bead defects.  This is also evident from the results of 
SEM analysis.  SPIN 5, 18 wt% solution, also produced non-beaded continuous fiber constructs.  
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However, the higher the solution concentration the larger the fiber diameter by a linear 
relationship and therefore, in order to achieve the smallest fiber diameter with no bead defects, 
the 15 wt% solution was selected.  Although the nano-fibers associated with beaded networks are 
ideal, the beads are disadvantageous to TEVG development because they decrease the much 
desired high surface per volume ratio achievable in fibrous electrospun constructs.  Cellular 
attachment and migration is also hindered by such large defects [139].  Micron-size fibers are 
acceptable in that they are smaller than the endothelial cells they will interact with and therefore 
acceptable for the ongoing of this investigation.   
 3.4.3 Optimizing Processing Parameters 
 Electrospinning process parameters were optimized for a solution of 15 wt% PLGA in 
CHCl3 in order to determine a final electrospinning protocol for further investigation of scaffold 
endothelialization.  Applied voltage and flow rate were the two parameters adjusted for 
processing optimization.  Voltage and flow rate in combination with solution viscosity must be 
in balance for stable jet formation and consistent fiber morphologies.  Comparisons between 
resultant fiber diameters and mechanical properties showed minor differences between constructs 
due to changes in applied voltage and flow rate.  This suggests solution viscosity has the ultimate 
control over final construct morphology as often shown in literature.  However, adjusting flow 
rate and applied voltage until a well balanced process is formed is optimum for process 
efficiency and repeatability.   
 Processing parameters in accordance with SPIN 6 will be used for all further 
investigations of PLGA.  The smallest achievable fiber diameter was seen for SPIN 6 with an 
average fiber diameter of 5.49  0.93 microns.  Such fiber diameters are smaller than the 
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endothelial cells they are intended to interact with and are acceptable for the continuation of this 
investigation.  The variation in fiber diameter for SPIN 6 could be explained by the high 
humidity (47%) during the spin.  High humidity could hinder solvent evaporation which may 
affect fiber consistency.  This trend is supported by results for SPIN 7 with an average fiber 
diameter of 5.85 ± 0.64 microns at only 40% humidity.  The only difference between SPIN 6 and 
SPIN 7 besides humidity was the flow rate, suggesting flow rate may also affect the consistency 
of fiber formation.  However, SPIN 8 with an average fiber diameter of 7.35 ± 1.00 microns was 
spun with 38% humidity and the same flow rate as SPIN 7 suggesting flow rate has minimal 
effect on consistency of fiber formation.  The major difference between SPIN 7 and SPIN 8 was 
applied voltage, ultimately suggesting an unstable jet from a high voltage causes the most 
inconsistency in fiber diameters of electrospun constructs.  Future studies should investigate the 
effects of a controlled environment (i.e. humidity and temperature) and the potential advantages 
to electrospun construct morphologies to confirm this hypothesis.  It should be noted that 
standard deviation could also be a result of a non-ideal measurement system using ImageJ and 
the potential for inaccurate measurements due to operator inconsistency.   
Processing parameters for SPIN 6 are advantageous for the final protocol for both time 
and efficiency purposes.  The flow rate used for SPIN 6 was set to 5.5 ml/hr which allows for 
approximately 1 spin every half hour, thus corresponding to six, 4 cm, scaffolds per hour.  At 5.5 
ml/hr and 12,000 V, a stable jet was formed from the droplet at the tip of the capillary during the 
electrospinning process.  For all spins regardless of flow rate and applied voltage, extruded 
droplet formations on the tip of the needle were observed.  This is disadvantageous since 
polymer is wasted during the process.  Such occurrences suggest solution viscosity is controlling 
droplet formation and further investigations will be necessary to make the process more efficient.  
 72 
 
However, SPIN 6 formed a consistent stable jet and no polymer was wasted due to stray jet 
formations or random collection around the collector and containment chamber.  Only minor 
amounts of stray polymer, as seen for all spins, was collected around the mandrel rotator cuffs.  
This was also consistent with the previous investigations of electrospun P(LLA-CL).     
Finally, results of tensile testing showed electrospun 15 wt% PLGA scaffolds had similar 
tensile strength in both circumferential and longitudinal directions compared to the native vessel.  
Young’s modulus in the circumferential direction was also comparable to that of native collagen.   
 In conclusion, a final protocol was developed for electrospinning PLGA for further 
investigations into a replacement scaffold for the BVM.  The final protocol uses PLGA dissolved 
in CHCl3 at a 15 wt% concentration.  All future spins will be electrospun at 5.5 ml/hr and 12,000 
V with a gap distance of 25.4 cm and an 18 GA blunt tip needle.  This was the optimum protocol 
determined for 15 wt% PLGA solutions.  PLGA scaffolds electrospun at the final protocol will 
be cultured in perfusion bioreactors, according to standard BVM practices, with human 
endothelial cells, to assess the formation of intimal cellular lining.    
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Chapter 4 – Evaluation of Electrospun PLGA for the BVM 
4.1 Introduction 
 The goal of this investigation is to evaluate cellular response of human umbilical vein 
endothelial cells (HUVECs) to electrospun 15 wt% PLGA constructs.  The implementation of 
electrospun polymer scaffolds could be advantageous in optimizing the scalability and cost 
effectiveness of the BVM model.  Electrospinning polymer scaffolds also allows for research 
expansion and scaffold optimization specifically for the BVM design.  PLGA is a promising 
material for tissue engineering vascular scaffolds and has shown good EC and SMC responses 
under pulsatile perfusion bioreactor systems [127].  The following investigation will evaluate 
electrospun 15 wt% PLGA scaffolds sodded with HUVECs and cultured under physiological 
conditions in a continuous-flow bioreactor system.  The potential for HUVECs to be sodded onto 
a PLGA scaffold and the subsequent formation of a luminal EC lining will be evaluated by 
fluorescent microscopy and histological staining.  Prior to cell culture, reactions of PLGA 
scaffolds to ethylene oxide gas sterilization, nutrient rich media, and BVM flow conditions will 
be investigated.  The purpose of those investigations is to ensure that the integrity of electrospun 
PLGA scaffolds will be persevered during the culture process.  All scaffolds used for this 
investigation are fabricated according to the final protocol developed in Chapter 3 of this thesis.    
4.2 Methods 
4.2.1   PLGA Response to Media 
The purpose of this investigation was to monitor the effects of PLGA in static growth 
media and consequences of degradation by-products and to observe scaffold integrity under 
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flow.  Bioreactor media was made by combining 500 ml M199, 56 ml fetal bovine serum (FBS), 
0.6 ml fungizone, 5 ml penicillin/streptomycin, 5 ml L-glutamine and 2.8 ml HEPES buffer.  
Media contains phenol red, an indicator of pH.  This is the same type of media used for BVM 
cultivation.  For static experiments, two small samples of 15 wt% PLGA scaffolds, from SPIN 4 
and SPIN 7, were placed in a 45 ml BD conical tube with media.  Samples in static media were 
placed in the large incubator at 37 °C.     
For flow experiments, two 4 cm PLGA scaffolds from SPIN 4 and SPIN 7 were used for 
flow analysis in the BVM.  Female leur to barb connectors were fitted to each end of the 
scaffolds and sutured on with 2-0 silk suture.  Each PLGA scaffold with connectors was fitted 
into a BVM chamber by non-sterile methods.  Enough media was added to each BVM chamber 
to cover the scaffold and approximately 40-45 ml of media was added to each reservoir.  
Chambers were closed and placed in the large ShelLab incubator and hooked up to a peristaltic 
pump ( 
Figure 28).  Flow was maintained through the lumen of the scaffolds at a flow rate of 15 
RPM.  All samples (static and flow) remained in the incubator until noticeable change occurred 
or after 3 days.  Scaffold samples under flow conditions were dried and preserved in a desiccator 
for further analysis.  The pH levels of both static and flow media was measured. 
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Figure 28 – The above picture shows both BVM chambers containing PLGA scaffolds 
hooked up to a peristaltic pump.  PLGA samples in static media (left) are located in the 
back of the green tube rack. 
 
4.2.2 Morphological Analysis of Samples from Flow Experiments 
 15 wt% PLGA scaffolds from SPIN 4 and SPIN 7 investigated under low flow conditions 
in the BVM were analyzed using the SEM.  Once dry, samples were removed from the 
desiccators and prepared according to section 3.2.2.1.  Images were taken for qualitative 
purposes only.     
4.2.3 Cell Selection and Culture 
 Human umbilical vein endothelial cells (HUVECs) were purchased from ScienCell 
Research Laboratories, Carlsbad, California and kept in vials in a liquid nitrogen dewar.  Vials of 
cells were thawed and cultured according to standard practices.  Endothelial cell media was 
made using 500 ml endothelial cell basal medium, 5 ml endothelial cell growth supplement, 5 ml 
of penicillin/streptomycin solution and 25 ml fetal bovine serum (Cat. No. 1001 from ScienCell).  
PLGA in static 
media 
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Cells were maintained in a small incubator at 37 °C and 5% CO2.  T225 BD cell culture flasks 
and endothelial cell media were used for the cell culture and expansion process. 
4.2.4 Preparation of Bioreactors and PLGA Scaffolds  
 Four 15 wt% PLGA scaffolds were electrospun based on the final protocol developed in 
Chapter 3.   Poly(D,L-lactide-co-glycolide) [75:25; PLGA; mol wt. 66,000 - 107,000; Cat. No. 
P1941] from Sigma Life Sciences and chloroform (CHCl3; 99.9%, extra dry, water <50 ppm; 
mol wt. 119.38; Cat. No. AC32682-0010_Acros Organics No.: 326820010) from Fisher 
Scientific were used for this experiment.  Four 15 wt % solutions of PLGA in CHCl3 were 
prepared according to Appendix B.  Calculations to determine grams polymer necessary for a 
given wt% solution were conducted based on 4 ml CHCl3.  Each solution was electrospun 
according to Appendix C.  Only 3 ml of the 4 ml solution was electrospun for each spin.  
Mandrel rotation was set to 6 and translation set to 3 for all spins.  Flow rate was set to 5.5 ml/hr, 
gap distance to 25.4 cm, and applied voltage to 12,000 V.  An 18 GA blunt needle was used for 
all spins.  During each spin, environmental conditions remained stable at 35% humidity and 68.8 
± 1 °F (normal conditions for that day).  At the end of each spin, scaffolds were allowed to dry 
overnight in the desiccator.  After that time, each spin was removed from the desiccator and cut 
into three 4 cm sections, placed on a glass stir rod and back in the desiccator for future use. 
 Five 4 cm sections of 15 wt% PLGA from the new spins, including one 4 cm section 
from SPIN 4 (from Chapter 3) were packaged and sent to the Cal Poly Veterinary Clinic to be 
Ethylene Oxide (EtO) gas sterilized for 24 hours.  Bioreactor chambers, chamber lids, two-port 
reservoir lids, bioreactor tubing and fittings were also sterilized in the same manner.   
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4.2.5 BVM Bioreactor Set-up with HUVECs 
 Bioreactor media and conditioning media were brought to 37 °C in a water bath.  All 
necessary sterile equipment was gathered.  Using sterile techniques, 4 sterilized scaffolds (3 new 
and one from SPIN 4) were sutured onto sterile luer lock fittings with silk suture and attached to 
the inside of the sterile bioreactor chambers.  PLGA scaffolds were too small for the BVM and 
additional sterile tubing was used to connect scaffolds in place.  Typically a denucleation step is 
necessary to remove air from ePTFE scaffolds prior to cell sodding, however this step requires 
prolonged static conditioning which should be avoided with spun PLGA due to previous results 
from section 4.2.1 (PLGA Response to Media).  Enough media was added to each BVM 
chamber to completely submerge the scaffold (Figure 29).   
 
 
Figure 29 - Preparation of BVM chambers for cell sodding in a sterile environment. 
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Each PLGA scaffold was actively syringe-primed with conditioning media by injecting 
media through the lumen of the scaffold until all the air was removed.  The luminal outlet was 
then closed and media was transmurally forced through the pores of the PLGA scaffold. 
Bioreactors with conditioning media were placed in a large ShelLab incubator and hooked up to 
a peristaltic pump.  Bioreactors were further primed with one hour of flow with conditioning 
media.  At the end of the conditioning process, each bioreactor was removed from the incubator 
and placed back in the sterile hood for cell sodding.  Each scaffold was sodded with 
approximately 1 million HUVECs per cm
2
 (approximately 7 million cells per scaffold) using 
sterile techniques.  Cells were pressure sodded and chased with 5 ml of media.  After sodding, 
media reservoirs were replaced with endothelial cell media.  Bioreactors with the new media 
were again set up in the large ShelLab incubator and connected to a peristaltic pump (Figure 30).  
The incubator was maintained at 37 °C and 5% CO2. 
 
Figure 30 - Final setup of BVMs in incubator and hooked up to peristaltic pump. 
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Once bioreactor setup was complete and cells were sodded, the luminal outlet remained 
closed and transmural flow was initiated for 5 minutes at 10 RPM.  Generally this step is 
conducted for one hour to aid cellular attachment to scaffolds by pushing cells into the pores.  
However, due to the highly porous nature of the electrospun PLGA scaffolds and the limited 
resistance experienced during pressure sodding, there was concern that too much prolonged 
pressure would force the cells to penetrate too deeply into the scaffold.  Following transmural 
flow, the pump was turned off for 20 minutes to allow time for cells to attach to the luminal 
surface of the scaffolds.  The luminal outlet port was opened and flow was set to 10 RPM for a 
few hours and then ramped up to 25 RPM and later to 55 RPM.  After 24 hours, one scaffold was 
harvested and the flow rate was set to 75 RPM for the remaining BVMs.  After 3 days in the 
incubator, a second scaffold was harvested and flow rate was set to 90 RPM for the remaining 
two scaffolds.  After 6 days in the incubator, the remaining two scaffolds were harvested. 
4.2.6 Harvesting of PLGA Scaffolds with HUVECs 
Scaffold harvesting was conducted with the removal of each BVM from the incubator 
according to the following protocol.  All valves were closed on the bioreactor and the BVM 
chamber, including media reservoir, was removed from the incubator to a non-sterile work 
station.  A 15 ml VWR conical tube was labeled appropriately and filled with approximately 10-
12 ml of histochoice fixative.  Each HUVEC sodded PLGA scaffold was removed from the 
chamber and barb fittings using a surgical scalpel #11.  Each scaffold was then transferred to one 
of the prepared histochoice tubes, proximal side down, and set aside for future use.  Residual 
PLGA was removed from the barb fittings and thrown away.  Media was disposed of and the 
bioreactor, tubing, and fittings were cleaned with hot water. 
 80 
 
4.2.7 Fluorescent Microscopy 
 Bis-benzimide (BBI, Em λ 460 nm) was the stain used for analysis of HUVECs on 
electrospun PLGA scaffolds.  In order to maintain the integrity of the BBI stain, the following 
procedures were conducted with minimum exposure to light.  Twenty-five ml of Milli-Q (non-
sterile) was placed in a 50 ml BD conical tube.  The tube was covered from the base to the lid 
with aluminum foil.  Twenty-five µl BBI was added to the tube containing Milli-Q and shaken 
vigorously.  Four 15 ml VWR conical tubes were wrapped in aluminum foil.  To each 15 ml 
tube, approximately 6 ml BBI solution was added.  PLGA scaffolds were removed from 
histochoice and prepared for BBI one at a time.  Each scaffold was cut into three samples; one 
cross section and two longitudinal sections. Approximately 1/3 of each scaffold on the distal end 
was cut for the cross sectional examination.  The remaining 2/3 of the scaffold was cut 
longitudinally to produce two samples for viewing the lumen of the scaffold.  The most proximal 
end of each section was notched with scissors to maintain orientation when imaging.  The three 
sections of each scaffold were placed in one of the 15 ml tubes containing BBI stain.  All 
samples remained in BBI for a minimum of 20 minutes and a maximum of 48 hours.  The longer 
soaking time was found to more brightly stain the cells for better imaging.  Images were acquired 
with an Olympus fluorescent microscope. 
4.2.8 Histology 
 Histology was performed on all cross-sectional samples for all harvested PLGA 
scaffolds.  The objective of histological analysis was to determine depth of cell penetration and 
presence of an endothelial cell lining.  From primary literature there was some concern as to 
whether PLGA electrospun scaffolds would maintain integrity during processing due to the use 
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of organic solvents.   However, processing was conducted according to traditional methods.  All 
samples were processed conventionally, embedded in paraffin wax, sectioned at 6 µm, then 
mounted on slides and stained with haematoxylin and eosin (H&E). 
4.2.9 SEM Analysis 
 HUVEC sodded PLGA scaffolds were also examined with the SEM.  Cultured PLGA 
longitudinal sections previously used for BBI staining were dried in the desiccator.  One end of 
each longitudinal section was cut for cross sectional examination.  All sections were sputter 
coated in gold and analyzed.      
4.3 Results 
4.3.1 PLGA Response to Media  
After 24 hours in static media at 37 °C, 15 wt% PLGA scaffolds turned the media bright 
yellow, indicating a highly acidic change from normal pH  to a measured pH of 4.82 (Figure 31).  
After one day, 15 wt% PLGA samples under flow conditions appeared unchanged and the media 
was a normal color.  After 3 days in the incubator under flow conditions, BVM media reservoirs 
became too low, allowing air into the tubes that stopped the continuous flow.  Consequently the 
test was terminated.  The pH of media in both chambers was measured.  A pH of 8.76 for SPIN 4 
and a pH of 7.6 for SPIN 7 were recorded.  No observable change in scaffold integrity was 
observed.  Degradation by-products did not cause an increase in acidity of the growth media.  It 
is necessary to maintain normal physiological pH when tissue engineering to maintain cell 
viability.  Reasons for no change in acidity for media in the BVM chambers could be due to the 
higher ratio of media to degradation by-products and the addition of gas permeable tubing.    
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Figure 31 - Image of media color changes due to acidic by-products of PLGA in static 
media. 
 
4.3.2 Morphological SEM Analysis of PLGA under Flow 
Results of SEM analysis show several points where fibers are broken or cracked (Figure 
32).  Possible occurrence of breakage could be due to lack of scaffold integrity under low flow 
and low shear conditions.  However, it is possible that fiber breakage was a result of drying the 
wet scaffolds in a desiccator immediately after removal.  It was observed that samples became 
cracked and fragile after drying in the desiccator prior to SEM preparation and analysis.  
 
Normal pH indicated 
by red media. 
Acidic pH indicated 
by yellow media 
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Figure 32 - The above SEM image was taken of the lumen of a PLGA scaffold after 72 
hours of luminal flow.  The image shows several broken and cracked fibers (487X). 
 
 
4.3.3 Preparation of Bioreactors and PLGA Scaffolds 
Electrospun PLGA scaffolds were successfully sterilized by EtO gas sterilization.  
However, scaffolds appeared squished from the process due to unknown causes and some 
scaffolds were more squished than others (Figure 33).  Since gas sterilization is conducted at the 
Cal Poly Vet Clinic, the process could not be monitored to determine cause of the deformed 
scaffolds.  Although squished, the scaffolds were relatively easy to open to expose the lumen for 
fitting the barb connectors.  For future sterilization, PLGA scaffolds should be pre-fitted to barb 
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connectors to keep the lumen open and to minimize the steps necessitating a sterile environment.  
It was also observed that PLGA scaffolds were stiffer after gas sterilization.  The increase in 
stiffness made scaffold insertion into the BVM chambers more difficult.  Each PLGA scaffold 
had been cut to 4 cm which should have allowed for easy insertion with the appropriate female 
and male fittings.  However, at that length, a little flexibility in the scaffold material is necessary 
to connect the scaffold into the BVM chamber.  In order to fit the PLGA scaffolds into the 
chambers, custom sized tubing was used to allow for the flex necessary to the secure the scaffold 
into place.  The adjustable tubing was fitted between the female luer to barb fitting and the inlet 
or outlet port fitting.   
 
 
Figure 33 - Original electrospun scaffold is shown on the left.  After gas sterilization the 
scaffold was severely flattened (right). 
 
4.3.4 Fluorescent Microscopy 
 The following table is a summary table of each HUVEC sodded and cultured PLGA 
scaffold that includes culture duration and flow rate upon removal.  A naming scheme was 
attributed to each scaffold based on time of removal for clarity and is provided in the table 
(Table VIII). 
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Table VIII - Summary Table of HUVEC Sodded PLGA Scaffolds 
Title Culture 
Duration 
Flow Rate 
BVM01 24 hrs 15 RPM 
BVM02 3 days 75 RPM 
BVM03 6 days 90 RPM 
BVM04 6 days 90 RPM 
 
The first construct to be removed from the incubator and fixed in histochoice was a final 
protocol 15 wt% PLGA scaffold.  From this point forward the scaffold will be referred to as 
BVM01.  Total duration of culture was 24 hours and maximum flow reached was 15 RPM.  BBI 
images of BVM01 showed definite appearance of cells on the lumen of the scaffold (Figure 34).  
One image is in black and white and the other in color.  This is because the color camera was not 
installed during initial imaging.  Cells look balled up as typically expected for such a short 
culture time.  The scaffold was difficult to image given the curved nature of the scaffold.  
Unclear images can be attributed to inexperience of the operator with BBI and fluorescent 
microscopy.      
 
Figure 34 - Images of BVM01 cultured with HUVECS for 24 hours under flow at 15 RPM.  
Both proximal (right) and distal (left) ends of the graph have visible cells (10X). 
Flow 
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The second PLGA construct to be removed from the incubator and fixed in histochoice 
was also a PLGA scaffold produced at the final protocol.  From this point forward the scaffold 
will be referred to as BVM02.  Total duration of culture was 72 hours and maximum flow 
reached was 75 RPM.  Cells can be observed on BVM02 from the distal to proximal end of the 
scaffold (Figure 35).  It appears that cells have penetrated deeper into the pores compared to 
BVM01.  Images for all scaffolds were taken at 10X and BVM02 cells seem slightly smaller 
than BVM01, alluding to the deep penetration hypothesis.   
 
Figure 35 - Images from BVM02 cultured with HUVECs for 3 days.  Cells are evident at 
both distal (right) and proximal (left) areas of the scaffold (10X). 
 
 The third and fourth PLGA constructs to be removed from the incubator and fixed in 
histochoice were a section from SPIN 4 and a final protocol PLGA construct.  From this point 
forward SPIN 4 will be referred to as BVM04 and the new construct will be referred to as 
BVM03.  Both BVM03 and BVM04 were cultured for 6 days and at a maximum flow rate of 90 
RPM.  There is little difference between the number of cells appearing on BVM03 (Figure 36) 
and BVM 04 (Figure 37) compared to BVM02 (Figure 35).  However cells do look smaller than 
Flow 
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those present on BVM01, again suggesting cells are penetrating deeper into the porous PLGA 
constructs.  The first round of imaging for BVM03 and BVM04 was difficult to obtain clear 
images therefore new BBI was made and scaffolds were allowed to soak for at least 24 hours 
before viewing.  Images were much brighter after soaking the additional time in new BBI 
solution.   
 
Figure 36 - Images of BVM03 show cells present for both distal (left) and proximal (right) 
regions of the scaffold. 
 
    
Figure 37 - Images of BVM04, both proximal (left) and distal (right), show several cells 
present. 
 
Flow 
Flow 
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The larger image included below was taken from BVM03 (distal) (Figure 38).  The 
image clearly shows fibers interweaving over and around cells, further suggesting the deeper 
penetration of cells into the PLGA scaffolds.  Histological analysis was conducted in order to 
determine depth of cell penetration and or presence of an intimal cellular lining. 
 
Figure 38 - The above image from BVM03 shows the fibrous nature of the PLGA scaffolds.  
Cells appear to be under some fibers. 
 
4.3.5 Histology 
 As mentioned previously, there was some concern as to the integrity of HUVEC sodded 
PLGA scaffolds when processed for histology with organic solvents.  After conventional 
processing, samples were removed and were noticeably smaller than their original size prior to 
processing.  Also, PLGA samples were squished and it was difficult to re-open the lumen 
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without damaging the structure of the samples.  Regardless, BVM01-04 were successfully 
embedded in wax.  During microtone slicing of samples, BVM02 (75 RPM, 72 hrs) fell out of 
the wax mold and staining of that sample was unable to be performed.  Histological imaging of 
BVM01, 03, and 04 shows clear evidence of damage to the scaffolds due to processing.  
Significant damage occurred for BVM03 (90 RPM, 6 days).  Images showed scattered cells at 
various locations in the polymer (Figure 39).  The shape observed was no longer an open lumen 
but a semi deformed circle. 
 
Figure 39 - Histology images of BVM03 shows cluster of cells and a damaged sample. 
 
 Deformation was also observed for BVM04 (90 RPM, 6 days).  The lumen of the sample 
was closed during wax embedding.  Images show a closed vessel with a cellular line following 
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the center of the vessel (Figure 40).  Even still the scaffold is clearly deformed and no conclusion 
can be drawn as to the exact location of the cells.   
 
Figure 40 - Histology shows the lumen of BVM04 was closed during processing.  A cellular 
lining is seen down the center of the vessel. 
 
Unlike BVM03 and BVM04, the lumen of BVM01 remained open and images of the 
cellular lining were obtained.  Still there is evidence of severe deformation of the scaffold from 
processing.  No conclusive evidence exists as to the penetration of cells given the severity of 
scaffold deformation and the potential disruption of the cellular lining.  It is possible that the 
cellular lining acted as a protective barrier for the polymer on the lumen, allowing for the images 
below. 
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Figure 41 – Histology images of BVM01 show a cellular lining on the lumen of the vessel. 
  
Unfortunately no conclusion can be drawn from histological analysis of HUVEC sodded 
PLGA scaffolds.  Scaffolds were highly deformed after conventional histological processing of 
the PLGA scaffolds suggesting a new process or a modified process needs to be investigated.   
4.3.6 SEM Analysis 
To further investigate an intimal lining and the depth of cellular penetration for HUVEC 
sodded PLGA scaffolds SEM analysis was employed.  Cells were apparent on the lumen of 
BVM01 (15 RPM, 24 hrs) [Figure 42].  The balled-up morphology of the cells is expected for 
such a short culture time point, however evidence of cell spreading can be seen (Figure 42). 
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Figure 42 - HUVEC sodded PLGA scaffold after 24 hrs continuous flow culture at 15 RPM.  
The appearance of some cell spreading is evident. 
 
 SEM images of BVM04 (90 RPM, 6 days) showed few areas of good HUVEC coverage 
on the lumen of the PLGA scaffold (Figure 43).  To date, this is the best cell spreading seen for 
HUVECs on any scaffold material in the Cal Poly Tissue Engineering Lab.       
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Figure 43 - HUVEC spreading shown on the lumen of the electrospun PLGA scaffold that 
was cultured for 6 days at 90PRM. 
 
No conclusion could be drawn for SEM analysis of scaffold cross sections for BVM01-
04.  However, images are a good example of the highly porous and fibrous architecture 
developed by electrospinning (Figure 44).  In addition, no cells were seen on the lumen of 
BVM02 and BVM03.  
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Figure 44 - Cross sectional image of BVM02 showing the fibrous nature of electrospun 
constructs. 
 
4.4 Discussion 
4.4.1 PLGA Response to Media 
 PLGA is a biodegradable polymer that degrades by hydrolysis and cleavage of the ester 
linkages.  By-products of PLGA include lactic and glycolic acid.  The degradation rate of PLGA 
is largely dependent upon ratios of PGA in the co-polymer with an increase in degradation 
corresponding to an increase in PGA.  The acidic nature of PLGA degradation by-products was 
evident in the static media test on 15 wt% electrospun PLGA samples.  In the same study it was 
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shown that electrospun PLGA scaffolds subjected to continuously circulating media did not 
cause an acidic change after 72 hours of flow.   Normal body pH is necessary for cell culture and 
the stable pH results of electrospun PLGA under flow supports the use of PLGA for tissue 
engineering vascular constructs for the BVM.   
Electrospun PLGA scaffolds have been used extensively for tissue engineering with a 
variety of cell cultures in different bioreactor systems.  Porous PLGA scaffolds have shown 
evidence of good cellular attachment and scaffold integrity under continuous flow culture 
systems [140].  Only one known study suggested electrospun PLGA vascular scaffolds placed 
under physiologic pressurized flow conditions will collapse as a result of low resistance to shear 
stress and rapid degradation [141].  Looking into the claim further, it was found that PLGA 
(50:50; PLA:PGA) was co-spun with collagen when collapse of scaffolds under physiological 
conditions was observed [142].  Therefore, lack of integrity of the PLGA(50:50)/collagen 
scaffold could be due to the faster degrading polymer and the addition of biologics in 
combination with high pressure and flow conditions.  Subsequently, integrity of electrospun 
PLGA (75:25) under low flow, low pressure conditions would be expected for the scaffold 
developed in this thesis.  However, SEM images of 15 wt% PLGA scaffolds exposed to low flow 
conditions showed multiple cracked and broken fibers on the vessel lumen.  Although flow 
cannot be ruled out, fiber breakage could be a result of drying of scaffolds in the desiccator when 
removed from the BVM chamber.  Scaffolds were noticeably cracked on the surface during SEM 
preparation after complete drying.  Also, scaffolds could have been mishandled during cutting 
and sectioning during the SEM preparation.  Another cause of cracking could be due to the age 
of the constructs before the start of the flow condition test.  Both SPIN 4 and SPIN 7 were 
produced several weeks before this test was conducted, with SPIN 4 being the oldest.  However, 
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there was no difference in appearance between the two constructs in terms of fiber morphology 
and breakage.  Overall fiber surfaces appeared smooth, which could support the hypothesis that 
drying caused the cracking and breakage of the fibers.  Results of tensile testing support stability 
of scaffolds under such low flow, low shear stress conditions due to good mechanical properties.  
However, SEM results of HUVEC sodded PLGA scaffolds presented later in this section, show 
no fiber breakage after 6 days of flow.  Further investigations would be necessary to determine 
the exact cause of fiber breakage.  In order to ensure integrity of the PLGA constructs, 
investigations should determine degradation rates under various durations of flow, and determine 
an alternative drying method prior to SEM analysis.  Also shelf life of the electrospun PLGA 
should be investigated to ensure constructs are used prior to the onset of degradation.  In 
conclusion, several controlled experiments would be necessary to determine the exact cause of 
fiber cracking after flow conditioning, as well as to ensure the structural integrity of electrospun 
PLGA scaffolds is stable during culture in the BVM system.    
4.4.2 Results of Electrospun PLGA Cultured with HUVECs  
BBI staining of HUVEC sodded 15 wt% electrospun PLGA scaffolds was conducted and 
results indicate the presence of cells within the pores on the luminal surface of the scaffolds.  
Results suggest electrospun PLGA scaffolds have potential for vascular tissue engineering as a 
replacement to ePTFE for the BVM system.  From a period of 24 hours to 6 days of culture, the 
presence of HUVECs on the lumen, in both proximal and distal directions to flow, had similar 
coverage qualitatively.  Results of BBI staining of the HUVEC sodded PLGA scaffolds also 
suggest that high porosity of electrospun constructs encourages cellular penetration below the 
luminal surface.  More specifically, the pore size allows for such cellular penetration.  Deep 
cellular penetration is ideal for creating a completely or mostly biological tissue construct in 
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vitro.  In contrast, the goal of the BVM model is to develop an intimal cellular lining of ECs to 
test the response of device implantation with the majority of the scaffold providing the necessary 
structural support of the media and adventia of the human blood vessel.  Therefore, the BVM 
design necessitates a scaffold that can adequately support an intimal lining of endothelial cells.  
To improve upon the current BVM model with HUVEC sodded constructs, electrospun PLGA 
scaffolds would need to be developed with smaller pore sizes.  Pore size is directly related to the 
fiber diameter for electrospun constructs.  In order to decrease the pore size, production of nano-
fibrous PLGA scaffolds, rather than micron sized, would need to be investigated. 
Results of the solution concentration study of this thesis suggest solution viscosity has the 
ultimate control over fiber size and consistency.  At lower solution viscosities, the presence of 
bead defects were observed which are inappropriate for tissue engineering, as discussed 
previously in the introduction of this thesis.  However, with further investigation of primary 
literature, lower solution viscosities can achieve continuous non-beaded fiber networks by 
adjusting the electrospinning gap distance and flow rate and by changing solution conductivity or 
surface tension [102].  Fiber diameters from 100 nm to 800 nm have been achieved for 
electrospun PLGA constructs when electrospun at a concentration of 1g PLGA in 4 ml 
THF:DMF (50:50); approximately the same ratio used for 15wt% PLGA in CHCl3 [132].  
Further, literature review of electrospun PLGA in solvents combining THF and DMF suggests 
changing the solvent could lead to nano-fibrous constructs with smaller pore diameters for better 
endothelialization of PLGA scaffolds for the BVM. 
 It can be hypothesized that the addition of DMF to THF lowers the volatility of the 
solvent, which would consequently allow for more fiber thinning during whipping instability 
prior to collection.  For example, a highly volatile solvent such as CHCl3 or THF alone may 
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evaporate almost completely before collection, thus limiting jet thinning during travel through 
the air.  There is also evidence of especially low flow rates leading to smaller fiber diameters in 
electrospun PLGA constructs, with nano-fibers achieved at flow rates from 0.1 ml/hr to 1.2 ml/hr 
[132].  Such low flow rates were not investigated in this thesis given the time that would be 
necessary to spin 3 ml of solution in order to produce one tissue engineering scaffold.  Although 
further investigation of lower flow rates adjusted for electrospinning PLGA would be interesting, 
the time to scaffold formation would be less than ideal and would not address the scalability and 
efficiency of the BVM model.  Gap distance has also been suggested as a possible parameter for 
controlling fiber diameter, however such investigations are minimal and more evidence is 
necessary, due to the complexity of varying processing parameters, to confirm the hypothesis.  In 
conclusion, in order to develop smaller pore sizes to limit HUVEC penetration from sub-luminal 
areas of electrospun PLGA scaffolds, further investigations of electrospinning processing 
parameters and solvent/polymer combinations should be investigated.  However, electrospun 
PLGA scaffolds with large pore sizes may be advantageous for investigating dual sodding 
techniques with SMCs and ECs.  The large pores may encourage SMC penetration to form a 
cellular lining followed by an EC lining on the luminal surface of the scaffold.  The SMC lining 
would act as barrier to EC penetration.   
Histology is a necessary and effective method of evaluating tissue engineered constructs.  
Electrospun PLGA scaffolds were processed with traditional histological procedures and H&E 
staining techniques in order to evaluate endothelialization of HUVECs on the lumen of the 
scaffolds and the cellular depth of penetration as a result of porous scaffold morphology.  From 
results of BBI staining, it was hypothesized that porosity of electrospun PLGA constructs was 
allowing for sub-luminal cellular penetration.  Histology would offer a method of confirming 
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that hypothesis.  However, during traditional histological processing, all PLGA scaffolds were 
destroyed or severely deformed.  This was further evident after H&E staining and imaging where 
evidence of deformed or melted polymer was clearly observed.  Further investigations of the 
potential cause lead to an article by Holy and Yakubovich on Processing Cell-Seeded Polyester 
Scaffolds for Histology [143].  The article specifically investigated alternative methods of 
cellular imaging for PLGA scaffolds cultured with cells in vitro.  According to the article, 
traditional histological techniques dissolve polyester scaffolds because of the temperatures and 
organic solvents used during the processing step where scaffolds are initially coated and 
infiltrated with paraffin wax [143].  Traditional processing, as used in this thesis, uses hot 
paraffin and a series of chemical purification steps for prolonged duration.  A new protocol was 
determined by Holy and Yakubovich that successfully stains and sections cultured PLGA 
scaffolds for H&E staining in a relatively fast and easy manner.  The process is carried out by 
first staining the PLGA samples with H&E prior to embedding and sectioning.  After staining is 
complete, the samples can be placed in a 10% poly(vinyl alcohol) [PVA] solution followed by 
freezing and cryosectioning [143].  After sectioning, PLGA samples can be further stained or 
mounted in gelatin mounting medium.  The use of this protocol was successful for in vitro cell 
cultured PLGA (75:25) with complete integrity of scaffold morphology achieved [143].  In 
conclusion, histology was unsuccessful for imaging electrospun HUVEC sodded PLGA 
scaffolds.  The presence of HUVECs was evident from the histology images; however due to 
severe scaffold deformation it is inclusive as to the exact location of a cellular lining and the 
depth of cell penetration.  All future histology of PLGA should be conducted in a non-traditional 
manner to avoid the use of harmful solvents and high temperatures.  Investigations into altering 
the histology processing steps or changing the solvents used can be investigated, however a 
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cryostat and cryosectioning protocol, similar to that provided by Holy and Yakubovich, would be 
the optimum choice to pursue for future electrospun PLGA scaffolds.  
Further analysis of HUVEC sodded PLGA scaffolds using SEM analysis provided better 
insight into cell penetration and coverage.  Although images were mostly inclusive, the presence 
of good HUVEC spreading on BVM04 is highly promising for the further optimization of 
electrospinning PLGA for ePTFE replacement.  Unfortunately cross sectional examination of the 
cultured PLGA scaffolds showed no evidence of where cells may have migrated if indeed sub-
luminal penetration had occurred.  Inconsistent cell coverage on the lumen of the PLGA 
scaffolds again suggests large pore size allows such cellular penetration thus limiting 
endothelialization on the scaffold lumen.  The absence of and inconsistency of cell coverage 
could also be a result of a poor HUVEC sodding and culturing protocols.  At the current time, 
there is no established protocol for sodding HUVECs on PLGA scaffolds in the Tissue 
Engineering Lab at Cal Poly.  Most of the process followed was experimental or based off of 
previous work with a different cell type on ePTFE.  It may be possible that more cells are needed 
during sodding to completely cover the PLGA constructs.  Also, flow rate may need to be 
ramped up at slower time points to avoid displacing cells from the lumen of the grafts before 
successful attachment can take place.  In addition, cells may have been lost due to mishandling 
during BBI staining and SEM preparation. 
In conclusion, electrospun PLGA scaffolds showed promising results for a potential 
replacement to ePTFE for the BVM model.  Optimization of the electrospinning protocol and 
alternative imaging methods should be investigated.   
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Chapter 5 - Discussion and Conclusions 
5.1 Overview 
Electrospinning is a polymer fabrication technique with promising application in the field 
of tissue engineering.  The process offers a relatively simple method of creating polymer 
scaffolds with micron to nano-sized fiber diameters in a highly porous network similar to the 
ECM of native tissue.  The high surface per unit volume ratio achieved in electrospun constructs 
is ideal for encouraging cellular attachment, proliferation and migration.  The primary aim of this 
thesis was to develop electrospun scaffolds for tissue engineering an in vitro blood vessel mimic 
(BVM) for intravascular device evaluation. 
Previously, Cardinal et al. demonstrated the feasibility of evaluating the response of an 
intimal lining of endothelial cells on the lumen of an ePTFE scaffold to stent implantation in 
vitro [3].  Such a model could allow for fast, reliable and economical testing of new intravascular 
devices coming to market prior to in vivo evaluation.  The original design by Cardinal et al. has 
several physiological limitations that must be addressed before effective and scalable use of the 
model can be initiated.  The use of ePTFE scaffolding does not meet the ideal criteria of the 
BVM design due to high cost, dependency on ePTFE suppliers, and the non-native mechanical 
properties that will have a significant effect on proper device response when compared to device 
responses in vivo.  In order to improve upon the limitations of the current scaffolding material 
and to increase the scalability and cost effectiveness of the BVM model, the potential for in-
house production of electrospun polymer scaffolds was investigated. 
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The first phase of investigating the effective use of electrospinning for tissue engineering 
vascular scaffolds was to select an appropriate polymer to be studied.   Poly(D,L-lactide-co-
glycolide) [PLGA] is one of the most well studied polymers for tissue engineering and has been 
effectively electrospun for a variety of tissue applications [131-133].  Due to controlled 
degradability, good mechanical properties, and evidence of good EC responses when cultured in 
vitro, PLGA was determined an appropriate scaffolding material for improving upon the current 
BVM model [127].   
In order to investigate the potential for in-house production of electrospun PLGA 
scaffolds as a replacement to ePTFE, the second phase of this thesis was to develop and optimize 
a PLGA electrospinning protocol.  The first task of protocol optimization was to study different 
solution concentrations of PLGA in CHCl3 and the resultant effects on electrospun fiber 
morphologies.  Results indicated that increased solution concentration leads to increased fiber 
diameters and more consistent fiber morphologies.  At 15 wt% PLGA solution concentration, 
optimum continuous fiber formations were created with fiber diameters of just a few microns.  
Solution concentrations less than 15 wt% PLGA led to increasing numbers of bead defects, 
which are known to hinder cellular attachment and migration [139].  A final protocol was then 
developed for electrospinning 15 wt% PLGA by optimizing flow rate and applied voltage.  
Electrospun constructs developed at different flow rates and electric field strengths were 
compared and evaluated based upon measured fiber diameter and mechanical properties.  The 
final protocol for electrospinning 15 wt% PLGA in CHCl3 included a flow rate of 5.5 ml/hr and 
an applied voltage of 12,000 V.  At this setting, fiber diameters were achieved between 5-6 
microns and radial tensile properties were similar to that of the native vessel (4-5 MPa).   
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The third phase of this thesis was to develop several PLGA scaffolds, produced at the 
final electrospinning protocol, for evaluating HUVEC response and the ability to form an intimal 
cellular lining when cultured in vitro.  Electrospun PLGA scaffolds were cultured from 1 to 6 
days in a continuous flow bioreactor according to standard BVM practices set by Cardinal et al.  
The presence of an EC lining was evaluated by BBI staining, histology, and scanning electron 
microscopy (SEM).  Results of BBI imaging showed good HUVEC coverage over the lumen of 
each scaffold for all culture durations and flow rates.  However, scaffolds cultured at 3 and 6 
days showed evidence of sub-luminal cellular penetration.  In order to confirm the results seen 
with BBI imaging, histological and SEM analysis was conducted.  From histology it was 
determined that PLGA constructs cannot withstand the aggressive processing used in traditional 
histological techniques and no further conclusions could be drawn from the processed sections.  
Alternative methods of processing and H&E staining were outlined in detail at the end of 
Chapter 4 of this report.  Further investigation of the remaining HUVEC sodded PLGA scaffolds 
with SEM did not confirm or disprove the deep cellular penetration hypothesis.  SEM images did 
show evidence of good cell attachment after 24 hours of culture at 15 RPM and areas of good 
HUVEC spreading after 6 days of culture and 90 RPM.  Endothelialization is critical to the 
success of the BVM model, and results of this study suggest electrospun PLGA scaffolds are 
promising for tissue engineering an in vitro blood vessel mimic with further optimization of the 
process.   
The importance of the scaffold during device evaluation in the BVM is to maintain 
structural integrity and to support an endothelial cell lining during culture and throughout the 
course of intravascular device evaluation.  An additional criterion for tissue engineering vascular 
scaffolds is found in the ECM mimicking micro-structural properties including porosity, pore 
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size, and general architecture (fibers, voids etc.) [60].  Pore size is critical to cellular migration 
and in-growth, as well as nutrient and waste transport.  Therefore, tailoring pore size could 
control the depth of cellular penetration in electrospun tissue engineering scaffolds.  Control over 
pore size and porosity is one of the attractive features of electrospinning.  Eichhorn et al. 
developed a model that suggests an increase in fiber diameter is directly proportional to an 
increase in pore size of electrospun constructs [110].  This model was confirmed by Balguid et 
al. who systematically evaluated cellular penetration in response to increasing fiber diameters 
when cultured with cells in vitro [87].  To improve upon the work of this thesis, electrospun 
PLGA scaffolds with nano sized fiber diameters should be developed to limit cellular penetration 
in order to support complete cell coverage on the luminal surface of the scaffold.   
To further improve upon the work of this thesis, mechanical properties of electrospun 
PLGA scaffolds should be addressed.  Although tensile properties for electrospun PLGA 
scaffolds were in an ideal range compared to that of the native vessel, Young’s modulus was 
much greater when compared to literature values.  This was evident in the great degree of 
stiffness observed during scaffold setup in the BVM chambers.  In addition, longitudinal 
mechanical properties were on average higher than their corresponding circumferential values.  
Radial compliance in response to flow and pressure fluctuations is of great importance when bio-
mimicking the native vessel.  It can be assumed that cellular response to device implantation will 
be largely dependent upon the response of the scaffold used in the BVM design.  In order to 
improve upon the current electrospun PLGA scaffolds, further optimization of processing 
parameters could lead to improved mechanical properties.  Studies have shown that fiber 
alignment can be used to increase radial compliance of electrospun tissue engineered vascular 
constructs [58].  Fiber alignment is attributed to the translation and rotation of the mandrel 
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during the electrospinning process.  In addition, fiber orientation could induce proper cellular 
alignment during culture.  One advantage to ePTFE is the nodal-fiber micro-architecture that 
induces cellular alignment with the direction of physiological flow.  The smooth surface 
associated with EC alignment is ideal for bio-mimicking the native vessel.  Therefore, further 
investigations into the optimization of rotational and translational speeds, and the corresponding 
effects on mechanical properties and cellular orientation should be conducted.           
In conclusion, the work of this thesis provides the basis for future optimization of 
electrospinning polymer scaffolds for tissue engineering vascular constructs and the optimization 
of an in vitro blood vessel mimic for intravascular device evaluation. 
5.2 Future Work 
5.2.1 Refinement of Electrospinning PLGA Protocol 
In order to improve upon the current PLGA electrospinning protocol to produce nano 
sized fiber diameters and subsequently smaller pore size, different processing parameters and 
solvent combinations should be investigated.  As discussed previously in Chapter 4 of this report, 
the addition of DMF to CHCl3 or THF, two highly volatile solvents, could increase the potential 
for producing nano-fibrous construct morphologies.  The solvent use may in fact be the greatest 
contributor to fiber diameter.  Other areas not investigated in the work of this thesis are needle 
size, gap distance, and controlled atmospheric conditions.  Of the three parameters not tested, 
gap distance may be the most beneficial aspect to pursue; although studies suggest only minor 
control of fiber size is contributed to gap distance [105].  Controlling atmospheric conditions 
would be costly to implement and nano-fibrous constructs have been produced consistently with 
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no such control.  Intuitively, needle size would seem to have a limited effect on morphological 
properties of electrospun scaffolds, none the less there is still potential for optimization.     
5.2.2  Improving the Electrospinning Apparatus 
The electrospinning apparatus used for the investigation laid out in this thesis was only 
recently developed and has several limitations that should be addressed for future studies using 
the device.  The following section outlines several areas that need improvement and 
recommendations as to how those areas can be improved. 
Containment chamber:  The containment chamber is the area in which the 
electrospinning apparatus, or more specifically the collector, is contained.  The containment 
chamber is a box closed on all sides, made of acrylic.  The front wall of the containment chamber 
is removable for easy access to the collector.  However, the current chamber design is unstable 
and the front wall does not securely stay in place.  A new chamber design should be developed.  
A simple, low cost fix would be to replace the front wall with a light weight acrylic piece, with 
hinges connecting the front wall to the top of the containment chamber. 
 Another addition to the containment chamber would be to add a straight edge tool at the 
base of the chamber.  During electrospinning setup, it is difficult to align the mandrel and 
collector perpendicular to the syringe and syringe pump.  An inexpensive, quick fix to this issue 
would be to laminate a grid and attach it to the bottom acrylic wall of the chamber.  The grid will 
also aid in measuring and adjusting the gap distance prior to each spin. 
High Voltage Power Supply:  A major disadvantage to the electrospinning apparatus is 
the high voltage power supply.  With the current system, there is no way to measure the exact 
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output voltage applied to the spin process and consequently no way to make fine tune 
adjustments.  The high voltage supply should be replaced with a more accurate system and one 
that will measure exact output voltage. 
Rotator Motor Control:  Mandrel rotation is necessary to wrap the polymer jet around 
the mandrel during electrospinning.  Orientation of polymer fibers can be controlled through 
mandrel rotation speed, with more radial oriented fibers achieved at faster rotational RPMs.  The 
rotator motor control box that controls both translation and rotation of the mandrel in the current 
electrospinning apparatus is a major limiting factor.  The current control box does not report 
rotational or translational speed.  Rotational speed would be necessary to investigate variations in 
fiber alignment, and the effects on scaffold mechanical properties and cellular response when 
cultured in vitro.  A simple method of fixing this issue would be to measure the speed at which 
the mandrel rotates using a tachometer.  In addition a new control box may be necessary if the 
high speeds necessary for fiber alignment cannot be reached with the current design. 
Syringe Pump Stage:  The syringe pump holds the syringe in place and regulates flow 
during electrospinning.  The stage on which the syringe pump sits is unstable and difficult to 
adjust.  A more mechanically stable stage would be a user friendly improvement to the 
electrospinning setup.   
5.2.3 Summary of Continuing Investigations 
The following section is to provide a summary of recommend studies for the future of 
electrospinning scaffolds for the BVM model.  Some of these suggestions were mentioned 
previously throughout this report.   
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Shelf Life:  Due to inconclusive results of fiber breakdown of PLGA scaffolds under 
flow, shelf life investigations should be conducted.  Shelf life will be an important aspect for any 
degradable polymer being investigated for the tissue engineering lab as it will be necessary to 
ensure scaffold integrity during culture and device evaluation. 
Sterilization:  Electrospun PLGA scaffolds returned from EtO gas sterilization severely 
squished and stiffer than their original form.  Re-opening the lumen of the scaffolds and inserting 
them into the BVM chambers was difficult as a result of this change.  Investigations into the 
primary cause of scaffold change will be necessary to ensure scaffold properties were not 
compromised due to gas sterilization.  Additional sterilization techniques possible for 
electrospun PLGA would be UV light radiation. 
PLGA Use for Dual-Sodding:  Results of 15 wt% electrospun PLGA scaffolds from the 
work of this thesis showed sub-cellular penetration.  An interesting study would be to dual sod 
these scaffolds with SMCs followed by ECs.  The larger pore size associated with micron sized 
fiber diameters could allow for a deeper SMC cellular layer that would act as a barrier for the EC 
layer to limit penetration.  Additionally, the SMC layer would allow for a more physiological 
representative tissue construct for device evaluation. 
Alternative Imaging Methods:  Traditional histological processing methods were too 
aggressive on electrospun PLGA scaffolds and consequently scaffolds were destroyed.  The use 
of xylene and the high temperatures during initial wax infiltration and processing was most likely 
the primary cause for breakdown of the PLGA.  Alteration of processing methods with different 
solvents and or time points should be investigated.  However, the use of a cryostat and 
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cyrosectioning may be the simplest and most effective alternative.  Refer to Chapter 4 for a more 
detailed review of cryostat processing.   
 Introduction of Biologics:  PLGA is still a promising alternative to ePTFE with further 
investigation.  Nevertheless, an alternative path to study would be PLGA/collagen composites.  
PLGA and collagen can be electrospun together and the combination has shown improved 
mechanical compliance similar to the native vessel [128].  However, PLGA/collagen composites 
were reported to not withstand the physiological pressures and flow rates in vitro [141].  Lee et 
al. showed the ability of PCL/collagen to be electrospun together in the same solution and the 
final constructs were able to promote cell adhesion in a pulsatile perfusion bioreactor for 4 weeks 
[141].  Still, incorporation of biologics into the electrospun constructs may provide an enhanced 
physiological representative construct for improved cellular response and intravascular device 
evaluation. 
5.3 Conclusion 
 The development of an in vitro blood vessel mimic for intravascular device implantation 
and evaluation could have great potential in pre-clinical testing of new vascular devices.  
Continued optimization of the current BVM needs to be addressed before effective use of the 
model can be initiated.  The introduction of electrospinning for in-house production of tissue 
engineering scaffolds addressed the scalability, cost effectiveness, and control over BVM design.  
Electrospun PLGA scaffolds are promising for tissue engineering vascular constructs for the 
BVM.  Future work is necessary to make the electrospinning process more efficient, as well to 
further optimize processing parameters to achieve nano-fibrous PLGA constructs for 
development of a confluent endothelial cell lining on the lumen of the scaffold.   
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Appendix A:  List of Abbreviations 
AHA – American Heart Association 
BD – Becton Dickenson 
BVM – Blood vessel mimic 
CABG – Coronary artery bypass graft 
CAD – Coronary artery disease 
CHD – Coronary heart disease  
CHCl3 – Chloroform 
CVD – Cardio vascular disease 
DMA – N,N-dimethylacetamide 
DMF – Dimethylformamide 
DNS – Does not state 
DTAB - dodecyltrimethylammonium 
EC – Endothelial cell 
ECM – Extracellular matrix 
ePTFE – Expanded poly(tetrafluoroethylene) 
EtO – Ethylene oxide (gas) 
FB – Fibroblasts 
FBS – Fetal bovine serum 
HEPES - 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
HCL – Hydrochloric acid 
HFP – 111333-hexafluro-2-propanol 
HUVECS – Human umbilical cord vein 
endothelial cells 
IMA – Internal mammary artery 
IPA – Isopropyl alcohol 
NA – Not applicable 
NIH – National Institute of Health 
NZW – New Zealand White 
PBS – Phosphate buffered saline 
PCI – Percutaneous coronary intervention 
PCL – Poly(ε-caprolactone) 
PDA – Personal digital assistant 
PDO – Poly(dioxanone) 
PET – Poly(ethyleneterephthalate) 
PGA – Poly(glycolic acid) 
PLA – Poly(lactic acid) 
PLCL – Poly(L-lactide-co-e-caprolactone) 
PLGA – Poly(D,L-lactide-co-glycolide) 
P(LLA-CL) – Poly(L-lactide -co-ε-
caprolactone) 
PTFE – Poly(tetrafluoroethylene) 
PU – Polyurethane 
PVA – Poly(vinyl alcohol) 
SMC – Smooth muscle cell 
SVG – Saphenous vein graft 
TEVG – Tissue engineered vascular graft 
TBAC - testrabutylammonium 
TFA – Trifluoroacetic acid 
THF – Tetrahyrdorfuran 
UTS – Ultimate Tensile Strength 
UV – Ultraviolet  
3D – Three dimensional 
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Appendix B: Mixing PLGA Solutions 
 
Materials/Equipment Vendor Part Number Quantity 
Poly(DL – lactide-co-glycolide) (PLGA) 
Lactide:Glycolide (75:25) 
Mol wt 66,000 - 107,000 
Sigma Life 
Science 
P1941-5G 5 grams 
Chloroform, extra dry, water <50ppm, stabilized 
Fisher 
Scientific, Inc 
326820010 1 Liter 
10 ml Syringe, Luer-Lok tip BD 309604 100/Pack 
Blunt Fill Needle, 18G 1½ (1.2 mm x 40 mm) BD 305180 100/Pack 
Analytical Balance Acculab ALC-80.4 1 
Orbital Shaker FinePCR SH130 1 
Vacuum-Pressure Pipette Aid 
Drummond 
Scientific Co. 
P-80991 1 
Serological Pipet 5 x 1/10 ml 
VWR 
International 
53283-706 NA 
Clear Glass Vial 20 ml 
VWR 
International 
15900-002 72/CS 
 
Procedure: 
1. Calculate the amount of PLGA resin necessary for the desired weight percent polymer 
solution using the following equation.  (Density of chloroform is 1.48 g/ml.) 
WPP = m1/ (m1 + m2b) 
WPP = Weight percent polymer solution 
m1 = mass of polymer (g) 
m2 = mass of solvent (ml) 
                       b = density of solvent (g/ml) 
 
2. Put on safety gloves. (WARNING: Chloroform can have serious side-effects if it comes in 
contact with skin, eyes or is inhaled or swallowed.  Target organs to be effected are kidneys, 
heart, central nervous system, liver, eyes, reproductive system and skin.  Always open 
chloroform in a hood and wear protective clothing!!) 
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3. Remove PLGA (Figure 45) from the freezer and allow it to reach room 
temperature (5-10 minutes).  Doing so prevents condensation when the 
polymer is exposed to air.  
 
4.  Weigh out the calculated amount of PLGA using the Acculab Balance 
(Figure 46) and place the polymer in a 20 ml clear vial.  Close the lid 
immediately. 
5. Return unused PLGA to the freezer. 
 
6. Retrieve the chloroform (Figure 47) for the hazardous chemical cabinet 
and place it in the fume hood immediately. 
 
7. Gather the Pipette-Aid (Figure 48), a 10 ml disposable pipette and the 
vial of weighed PLGA and place in the hood with the chloroform.  
 
8. Pipette the desired volume of chloroform into the vial with PLGA.  
Immediately cap the vial as well as the chloroform container to prevent evaporation of 
chloroform since it is highly volatile. 
9. Properly label the solution vial with the WPP, date and your initials 
(Figure 49).  
 
Figure 48 - Pipette 
aid for obtaining 
solvent. 
Figure 45 - A 5g bottle 
of PLGA from Sigma. 
Figure 46 - The 
Acculab balance. 
Figure 47 - A 1 liter 
bottle of chloroform. 
Figure 49 – 20 ml vial with 
solution and label. 
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10. Wrap vial in aluminum foil to prevent light from entering the 
solution (chloroform is highly sensitive to light). 
 
11. Place the vial on the orbital shake table (Figure 50).  Set the 
shake table to approximately 3 revolutions per second.  Use 
tape to ensure that the vial will stay upright while on the shake 
table.  Turn the table on. 
 
12.  Allow the solution to mix for 24 hours.  After mixing is complete, the solution is usable for 
up to 48 hours. 
13. Remove chloroform container from hood and place back into chemical cabinet. 
 
14. Properly dispose of pipette tip. 
 
15. Clean up work area. 
Figure 50 - Orbital shake table for 
mixing solutions. 
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 Appendix C:  Electrospinning Protocol 
WARNING: This electrospinning process requires extremely high voltages! Always wear 
shoes, gloves, and be mindful of what you are touching. Do not attempt to use the 
electrospinner unless you have been trained by a qualified user. 
 
1.  Put on safety gloves and protective clothing. (WARNING: Chloroform can have serious 
side-effects if it comes in contact with skin, eyes or is inhaled or swallowed.  Target organs 
to be effected are kidneys, heart, central nervous system, liver, eyes, reproductive system and 
skin.  It is possible for residual chloroform to be present on and around the electrospinner 
during and after a spin!! Make sure to read the MSDS for all chemicals you are working with 
and know the necessary emergency procedures.) 
2. The green ground wire located on the backside of the collector 
can be removed by pulling it straight out.  Unplug the green 
ground wire from the collector (Figure 51).  
3. The yellow power wire connects the collector to the DC motor 
control box.  The yellow power wire comes off the DC motor 
control box by unscrewing the connection head. Unscrew the 
yellow power wire from the DC motor control box (Figure 52).  
4. The collector can now be removed from the containment 
chamber.  Remove the collector from the containment chamber 
and place it on the counter outside the fume hood (Figure 53).  
5. During a spin, stray polymer preferentially builds up on 
Figure 51 - Green ground 
wire on back of collector. 
Figure 52 - Yellow power 
wire connects DC control 
box. 
Figure 53 - Entire collector. 
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exposed metal, wires and the motor casing.  Cleaning before 
each spin is necessary to remove any residual polymer or dust 
from the collector that may potentially interfere with the next 
spin process.  Clean the collector using IPA and paper towels.  
Ensure all residues from both the front and back of the collector 
including the wires are removed (Figure 54).  
6. During a spin, stray polymer can attach to any wall of the containment chamber and even 
form webs of polymer between walls.  If necessary, clean the inside of the containment 
chamber with IPA. 
7. Replace the collector back inside the containment chamber and reconnect the green ground 
and yellow power wires. 
8. Prepare the mandrel for spinning.  Clean the mandrel with IPA to remove any dust, residual 
polymer from a previous spin, or metal particles.  If the mandrel surface is scratched, fine grit 
sand paper can be used to re-smooth the surface of the mandrel.  If sanding is necessary, 
clean the mandrel with IPA when finished. 
9. Attach the mandrel to the collector.  When inserting the mandrel, rotate the turn knob until 
most of the metal chuck is covered, you will feel some resistance.  If you go too far the turn 
knob will spring back.    
10. There are three power cords to the right of the fume hood; one for the external power supply, 
one for the main power and one for the DC motor control box.  Plug in all the equipment. 
Figure 54 - Polymer residue 
on wires. 
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11. Using a multimeter, check the resistance between the ground 
connection and the mandrel.  Verify that there is some 
conductivity.  Record your measurements (Figure 55).  
12. In the fume hood, prepare a 10 ml syringe with an 18GA fill 
needle. 
13. Remove aluminum foil from the PLGA solution vial for better 
visibility when working with the solution. 
14. Solutions may be highly viscous and filling the syringe may take 
time and require some strength.  Make sure to not release pressure on 
the plunger when drawing solution into the syringe.  Acquire just 
over 3 ml of the polymer solution into the prepared 10 ml syringe 
(Figure 56).  
15. Once the solution has been acquired in the syringe, replace the fill needle with an 18GA 
Blunt needle. 
16. Push the plunger back into the syringe until most of the air is removed and the solution is just 
in the needle.  WARNING:  If you push too hard too fast the polymer melt may squirt out.  If 
this happens you will need to attach a new needle. 
17. Place the filled 10 ml syringe into the syringe pump.  The needle 
should go through the needle tip hole in the containment 
chamber wall (Figure 57). 
Figure 55 - Checking 
resistance between mandrel 
and ground wire. 
Figure 56 - Acquiring 
solution into syringe. 
Figure 57 –Positioned 
syringe in the pump. 
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18. Re-position the collector in the containment chamber so that the 
mandrel and the needle tip are 10 inches apart and 
perpendicular to each other (Figure 58).  NOTE:  The side of the 
collector with green ground wire connection should face away 
from the needle.  
19. Hang the exposed metal of the red high voltage wire on the 
needle tip inside the containment chamber.  You can secure the 
wire on the needle by taping the wire to the containment 
chamber wall (Figure 59).  WARNING:  If the wire falls off the 
needle during the spin, the external 10 V power source used to 
regulate high voltage output will burn out.  Be sure to hang the 
wire on the needle securely! 
20. The power switch for the syringe pump is located on the back of the pump.  Turn the syringe 
pump on. 
21. Enter the desired flow rate and solution volume.  The solution volume will determine when 
the pump will stop.  Make sure the screen remains on volume.  NOTE:  Syringe pump 
instructions are located in a cabinet close to the fume hood if you need further instructions. 
22. Turn on the “Rotate” and “Slide” functions of the collector at the 
DC motor control box.  Ensure the collector is now oscillating back 
and forth and the mandrel is rotating.  If the mandrel is not rotating, 
you can tap it gently to get it started (Figure 60). 
Figure 59 - Red wire hung on 
needle. 
Figure 58 - Proper 
positioning of the collector. 
Figure 60 - DC motor 
switches. 
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23. Place the front wall onto the containment chamber.  The 
bottom right corner of the front wall is cut for wires to run 
through.  Secure the wall in place with tape so it does not come 
off (Figure 61).  
24. Turn on the external power source and set it to the desired 
voltage.  Turn the external power source off (Figure 62). 
 
Read Steps 25-40 BEFORE beginning the electrospinning process.  The following steps for 
turning ON and OFF the electrospinning system must be followed in the exact order listed. 
25. Press the “Run” button on the syringe pump.  The volume count will begin on the screen and 
an arrow will flash meaning the solution is now being pushed through the needle.   
26. When a droplet forms on the tip of the needle, the process is 
ready to begin. 
27. Turn on the “Main Power” (left switch).  Power is on if the light 
on the AC/DC power converter turns green (Figure 63).  
28. Turn on the external source. 
29. Prepare to turn on the High Voltage (right switch) [Figure 64].  
Look at the droplet of polymer on the end of the syringe and 
turn High Voltage on.  The droplet should disappear. 
Figure 61 - Front wall placed 
on chamber. 
Figure 62 - The external 
power supply. 
Figure 63 - The Main Power 
switch. 
Figure 64 - High Voltage 
switch. 
 130 
 
30. Monitor the process for the entire spin.  The mandrel should slowly start to become coated 
with the polymer.   
31. When all the polymer have been spun, the process should be shut down in the following 
order. 
a. Press the RUN/STOP button on the syringe pump. 
b. Turn the HV switch to OFF 
c. Turn the Main Power OFF 
d. Turn the ROTATE and SLIDE functions on the DC Motor Control box OFF. 
32. In order to allow the solvent to fully evaporate, wait a few minutes before removing the 
mandrel from the containment chamber. 
33. Remove the front containment chamber wall. 
34. Remove the mandrel with PLGA scaffold. 
35. Touch the red high voltage wire to the green ground wire to remove any residual charge. 
36. Remove syringe from syringe pump and dispose in sharps container. 
37. Unplug all equipment. 
38. Properly dispose of all waste and clean up your work station.   
39. Transfer the mandrel with the PLGA scaffold to the desiccators for further drying of the 
scaffold.  Allow the scaffold to remain on the desiccators for 24 hours. 
40. Remove the scaffold from the mandrel using gauze and carefully twist the scaffold off. 
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Appendix D:  303 SS Mandrels 
Materials Vendor Part Number Quantity 
303 Stainless Steel, Unpolished 
 (diameter = 4 mm, length = 1 m) 
*Precision Ground not required 
McMaster Carr 1274T13 1 
Small Diameter Drill Bit  
(1/16’’ diameter, 1/8’’ shank) 
McMaster Carr 2841A94 1 
Stainless Steel Slotted Spring Pins 
(1/16
’’
diameter, ½
’’
length) 
McMaster Carr 92383A106 100/Pkg 
  
**WARNING:  Do not attempt to use the lathe if you have not been properly trained in all 
operating procedures as well as safety protocols.  The lathe can cause severe injury if used 
improperly! 
1. Read and understand all instructions before beginning fabrication. 
2. If you have any questions regarding this SOP or machinery operations, contact Dr. 
Kristen Cardinal for assistance. 
3. Cut the 1 meter stainless steel rod into 15 cm sections using horizontal and/or vertical 
band saws.  There will be six 15 cm sections and a small scrap portion of steel left at the 
end.  (Note: the final length of each mandrel will be 14 cm).    
4. Using a lathe, position the bulk of the 15 cm rod in the chuck, leaving only a small 
amount of material exposed.  Face one end of each 15 cm rod using a carbide-tipped lathe 
tool.  Set the speed to 1,170 RPM.  Chamfer the faced edges using a fine file; there is no 
need to adjust the speed for this.    
5. Prior to drilling the 1/16’’ hole, the surface of the rod must be prepared.  To prevent bit-
wandering and provide a better drill bit-surface contact, a file should be used to slightly 
grind a flat surface on the rod before drilling.   
6. Before drilling the hole, provide a few drops of cutting fluid to the bit to help with 
lubrication.  (Note: The key to drilling this size hole is to move slowly and peck the 
material frequently, however be careful as to not work harden the steel).  Using a CNC 
mill, drill a 1/16
’’ 
hole through diameter of each 15 cm rod, approximately 3 mm from the 
finished/chamfered end to the center of the hole.  Set drill speed to 2,300 RPM and use 
the 1/16
’’
 small diameter drill bit (1/8
’’
 shank).   
7. Using the lathe, face the unfinished end of each 15 cm rod.  Set speed to 1,170 RPM.   
8. Using a #2 drill bit on the lathe, drill a shallow hole into the faced/un-chamfered end of 
each 15 cm rod.  Drill just deep enough to attach a live center.  Do this for all 15 cm 
sections of steel.  Set speed to 1,170 RPM. 
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9. Secure the 15 cm rod between the live center and the chuck of the lathe.  Expose as much 
of the rod as is possible.  Set speed to 510 RPM.  Wet-polish the rod using 600 grit 
sandpaper and methanol or water.  (Note: If dirty or greasy, clean rods before polishing to 
remove particles and to achieve a better surface finish). 
10. Cut the 15 cm rods down to 14 cm ensuring to remove the face with the #2 drill bit hole.  
Use a band saw to remove the bulk of the material, leaving just enough material to finish 
the end. 
11. Using the lathe, face and chamfer the unfinished end following the same procedure as in 
step 2. 
12. Insert a 1/16’’ slotted spring pin into the 1/16’’ hole that was drilled in step 3.  This can be 
best achieved by crimping one end of the pin with pliers to get the pin partly inserted.  
Then using the pliers, force the pin into the center of the hole. 
13. Clean mandrels thoroughly with IPA before use to ensure all oil, dirt and metal particles 
are removed. 
14. Evaluate each mandrel manufactured by ensuring the mandrel properly fits and rotates in 
the electrospinner.  Also, perform a test spin on each mandrel and check for any 
differences between polymer collection and scaffold removal compared to that of the 
original mandrels.  The new mandrel should be nearly identical to the original.  If 
scaffolds are difficult to remove from the mandrels, further wet polishing on the lathe 
may be necessary (See Step 6). 
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Appendix E:  ImageJ Protocol 
1.  Open program ImageJ.  The following screen will appear. 
 
 
 
3.  Select File > Open.  Open a saved SEM image.  The image will appear in a separate screen. 
 
 
 
4.  Select  and draw a line along the SEM image’s scale bar.  Visually ensure the line is as 
close to the length of the scale bar as possible as this will affect the outcome of fiber diameter 
measurements (See image under Step 5 for further clarification).  
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5.  On the tool bar, select Analyze > Set Scale.   
 
 
 
5.  Insert known image scale bar distance (ex. 20 µm).  Set pixel aspect ratio to 1.0 and set 
appropriate unit length (ex. µm).  Selcect OK.  ImageJ is now calibrated to the image. 
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6.  From the tool bar, select .  Draw a line across the diameter of a single fiber to be 
measured. 
 
 
 
7.  From the toolbar select Analyze > Measure.  ImageJ will open a new window reporting 
Results.  Fiber diameter is reported as Length in the Results window in proper units (ex. µm).   
 
 
 
8.  Leave the Measure window open and repeat Step 6 for all fiber measurments for that image.   
 
9.  Repeat for all images.  NOTE:  Calibration is only necessary for the first image ONLY if all 
images being analyzed are at the SAME magnification.  Re-calibration will be necessary for 
images taken at different magnifications. 
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Appendix F:  Fiber Diameter Measurements 
 SPIN 11 - LUMEN SPIN 12 - LUMEN SPIN 13 - LUMEN SPIN 10 - LUMEN 
 
IMAGE 
FILE 
MICRONS 
IMAGE 
FILE 
MICRON
S 
IMAGE 
FILE 
MICRON
S 
IMAGE 
FILE 
MICRON
S 
1 Sample 006 4.66 
Sample 
051 
7.11 
Sample 
021 
6.11 
Sample 
036 
5.52 
2 Sample 006 6.25 
Sample 
051 
6.75 
Sample 
021 
6.39 
Sample 
036 
5.78 
3 Sample 006 6.17 
Sample 
051 
7.28 
Sample 
021 
7.06 
Sample 
036 
6.03 
4 Sample 006 5.21 
Sample 
051 
7.47 
Sample 
021 
7.54 
Sample 
036 
7.21 
5 Sample 006 6.41 
Sample 
051 
7.73 
Sample 
021 
7.24 
Sample 
036 
6.79 
6 Sample 007 5.37 
Sample 
052 
8.45 
Sample 
022 
6.23 
Sample 
037 
6.86 
7 Sample 007 6.01 
Sample 
052 
7.44 
Sample 
022 
4.39 
Sample 
037 
4.25 
8 Sample 007 6.41 
Sample 
052 
7.45 
Sample 
022 
6.27 
Sample 
037 
5.48 
9 Sample 007 6.69 
Sample 
052 
6.46 
Sample 
022 
5.70 
Sample 
037 
5.59 
10 Sample 007 6.29 
Sample 
052 
6.58 
Sample 
022 
6.60 
Sample 
037 
5.43 
11 Sample 008 5.75 
Sample 
053 
8.10 
Sample 
023 
5.69 
Sample 
038 
6.69 
12 Sample 008 5.95 
Sample 
053 
6.78 
Sample 
023 
6.25 
Sample 
038 
6.69 
13 Sample 008 5.37 
Sample 
053 
6.46 
Sample 
023 
6.37 
Sample 
038 
5.94 
14 Sample 008 5.75 
Sample 
053 
5.22 
Sample 
023 
5.56 
Sample 
038 
5.35 
15 Sample 008 6.72 
Sample 
053 
6.40 
Sample 
023 
7.21 
Sample 
038 
5.75 
16 Sample 009 6.01 
Sample 
054 
7.29 
Sample 
024 
6.18 
Sample 
039 
5.80 
17 Sample 009 6.52 
Sample 
054 
4.60 
Sample 
024 
6.62 
Sample 
039 
4.61 
18 Sample 009 6.39 
Sample 
054 
6.18 
Sample 
024 
6.60 
Sample 
039 
5.94 
19 Sample 009 7.06 
Sample 
054 
7.46 
Sample 
024 
6.67 
Sample 
039 
6.25 
20 Sample 009 5.98 
Sample 
054 
6.37 
Sample 
024 
6.99 
Sample 
039 
5.01 
21 Sample 010 6.36 
Sample 
055 
7.00 
Sample 
025 
6.33 
Sample 
040 
5.10 
22 Sample 010 6.89 Sample 5.98 Sample 6.36 Sample 5.31 
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055 025 040 
23 Sample 010 6.76 
Sample 
055 
7.68 
Sample 
025 
4.95 
Sample 
040 
5.34 
24 Sample 010 5.78 
Sample 
055 
7.43 
Sample 
025 
5.70 
Sample 
040 
4.28 
25 Sample 010 6.39 
Sample 
055 
8.14 
Sample 
025 
6.03 
Sample 
040 
5.81 
26 Sample 012 6.37 
Sample 
061 
7.48 
Sample 
026 
6.01 
Sample 
041 
4.50 
27 Sample 012 4.60 
Sample 
061 
6.27 
Sample 
026 
5.30 
Sample 
041 
7.14 
28 Sample 012 5.15 
Sample 
061 
7.58 
Sample 
026 
6.51 
Sample 
041 
5.22 
29 Sample 012 5.38 
Sample 
061 
6.84 
Sample 
026 
4.39 
Sample 
041 
4.15 
30 Sample 012 5.59 
Sample 
061 
6.78 
Sample 
026 
5.22 
Sample 
041 
5.39 
31 Sample 013 5.15 
Sample 
062 
8.29 
Sample 
027 
6.07 
Sample 
042 
5.82 
32 Sample 013 5.98 
Sample 
062 
8.23 
Sample 
027 
5.37 
Sample 
042 
5.89 
33 Sample 013 6.17 
Sample 
062 
7.35 
Sample 
027 
6.05 
Sample 
042 
5.39 
34 Sample 013 5.79 
Sample 
062 
7.65 
Sample 
027 
6.99 
Sample 
042 
5.34 
35 Sample 013 6.92 
Sample 
062 
7.65 
Sample 
027 
5.58 
Sample 
042 
4.68 
36 Sample 014 5.00 
Sample 
063 
6.52 
Sample 
028 
5.63 
Sample 
043 
4.80 
37 Sample 014 4.86 
Sample 
063 
7.71 
Sample 
028 
6.45 
Sample 
043 
5.76 
38 Sample 014 6.44 
Sample 
063 
7.65 
Sample 
028 
6.14 
Sample 
043 
5.18 
39 Sample 014 5.24 
Sample 
063 
7.53 
Sample 
028 
5.84 
Sample 
043 
4.57 
40 Sample 014 5.73 
Sample 
063 
7.55 
Sample 
028 
6.12 
Sample 
043 
5.24 
41 Sample 016 4.93 
Sample 
064 
7.55 
Sample 
029 
6.50 
Sample 
044 
5.53 
42 Sample 016 5.89 
Sample 
064 
10.19 
Sample 
029 
7.02 
Sample 
044 
5.33 
43 
 
Sample 016 
 
5.27 
Sample 
064 
7.09 
Sample 
029 
6.74 
Sample 
044 
5.65 
44 Sample 016 5.46 
Sample 
064 
7.63 
Sample 
029 
5.93 
Sample 
044 
4.87 
45 Sample 016 5.58 
Sample 
064 
6.39 
Sample 
029 
7.01 
Sample 
044 
4.73 
46 Sample 017 5.73 
Sample 
065 
6.28 
Sample 
030 
3.98 
Sample 
045 
5.34 
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47 Sample 017 6.04 
Sample 
065 
8.77 
Sample 
030 
4.97 
Sample 
045 
5.50 
48 Sample 017 5.86 
Sample 
065 
6.82 
Sample 
030 
6.59 
Sample 
045 
4.33 
49 Sample 017 6.80 
Sample 
065 
7.86 
Sample 
030 
5.86 
Sample 
045 
5.55 
50 Sample 017 5.07 
Sample 
065 
9.59 
Sample 
030 
6.21 
Sample 
045 
5.56 
51 Sample 018 6.48 
Sample 
071 
7.73 NA NA 
Sample 
046 
5.84 
52 Sample 018 5.59 
Sample 
071 
7.45 NA NA 
Sample 
046 
5.60 
53 Sample 018 6.38 
Sample 
071 
8.43 NA NA 
Sample 
046 
7.20 
54 Sample 018 6.27 
Sample 
071 
6.11 NA NA 
Sample 
046 
6.08 
55 Sample 018 6.64 
Sample 
071 
8.48 NA NA 
Sample 
046 
5.79 
56 Sample 019 5.88 
Sample 
072 
7.59 NA NA 
Sample 
047 
5.07 
57 Sample 019 6.13 
Sample 
072 
9.18 NA NA 
Sample 
047 
5.67 
58 Sample 019 5.42 
Sample 
072 
6.48 NA NA 
Sample 
047 
6.42 
59 Sample 019 5.59 
Sample 
072 
8.48 NA NA 
Sample 
047 
4.80 
60 Sample 019 4.24 
Sample 
072 
5.69 NA NA 
Sample 
047 
5.46 
61 Sample 020 5.93 
Sample 
073 
6.91 NA NA 
Sample 
048 
6.17 
62 Sample 020 5.39 
Sample 
073 
7.48 NA NA 
Sample 
048 
5.49 
63 Sample 020 5.85 
Sample 
073 
5.48 NA NA 
Sample 
048 
5.22 
64 Sample 020 5.41 
Sample 
073 
7.12 NA NA 
Sample 
048 
4.36 
65 Sample 020 6.02 
Sample 
073 
7.55 NA NA 
Sample 
048 
5.70 
66 
 
Sample 001 
 
4.15 
Sample 
074 
7.97 NA NA 
Sample 
049 
6.64 
67 Sample 001 5.82 
Sample 
074 
8.65 NA NA 
Sample 
049 
5.59 
68 Sample 001 5.53 
Sample 
074 
9.07 NA NA 
Sample 
049 
5.58 
69 Sample 001 6.29 
Sample 
074 
6.72 NA NA 
Sample 
049 
0.19 
70 Sample 001 6.50 
Sample 
074 
8.94 NA NA 
Sample 
049 
4.49 
71 NA NA NA NA NA NA Sample 5.76 
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050 
72 NA NA NA NA NA NA 
Sample 
050 
5.86 
73 NA NA NA NA NA NA 
Sample 
050 
5.99 
74 NA NA NA NA NA NA 
Sample 
050 
6.19 
75 NA NA NA NA NA NA 
Sample 
050 
5.98 
 MEAN 5.85 MEAN 7.35 MEAN 6.11 MEAN 5.49 
 STDEVE 0.64 STDEVE 1.00 STDEVE 0.75 STDEVE 0.93 
 MIN 4.15 MIN 4.60 MIN 3.98 MIN 0.19 
 MAX 7.06 MAX 10.19 MAX 7.54 MAX 7.21 
 MODE 6.41 MODE 7.45 MODE 4.39 MODE 5.34 
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Appendix G:  Results of Tensile Testing 
 
Figure 65 - Tensile strength for SPIN 4, 15 wt% PLGA in CHCl3 (5.5 ml/hr; unknown). 
 
 
Figure 66 - Longitudinal Young's modulus for SPIN 4, 15 wt% PLGA in CHCl3 (5.5 ml/hr; unknown).  
 
 
Figure 67 - Circumferential Young's modulus for SPIN 4, 15 wt% PLGA in CHCl3 (5.5 ml/hr; unknown). 
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Figure 68 - Tensile strength for SPIN 6, 15 wt% PLGA in CHCl3 (5.5 ml/hr; 12,000 V). 
 
 
Figure 69 - Longitudinal Young's modulus, SPIN 6, 15 wt% PLGA in CHCl3 (5.5 ml/hr; 12,000 V). 
 
 
Figure 70 - Circumferential Young's modulus, SPIN 6, 15 wt% PLGA in CHCl3 (5.5 ml/hr; 12,000 V). 
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Figure 71 - Tensile strength for SPIN 7, 15 wt% PLGA in CHCl3 (3.0 ml/hr; 12,000 V). 
 
 
 
Figure 72 - Circumferential Young's modulus, SPIN 7, 15 wt% PLGA in CHCl3 (3.0 ml/hr; 12,000 V). 
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Figure 73 - Tensile strength for SPIN 8, 15 wt% PLGA in CHCl3 (3.0 ml/hr; 15,600 V). 
 
 
Figure 74 - Longitudinal Young's modulus, SPIN 8, 15 wt% PLGA in CHCl3 (3.0 ml/hr; 15,600 V). 
 
 
Figure 75 – Circumferential Young's modulus, SPIN 8, 15 wt% PLGA in CHCl3 (3.0 ml/hr; 15,600 V). 
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Figure 76 - Tensile strength for SPIN 9, 15 wt% PLGA in CHCl3 (5.5 ml/hr; 15,600 V). 
 
 
Figure 77 - Longitudinal Young's modulus for SPIN 9, 15 wt% PLGA in CHCl3 (5.5 ml/hr; 15,600 V). 
 
 
Figure 78 - Circumferential Young's modulus for SPIN 9, 15 wt% PLGA in CHCl3 (5.5 ml/hr; 15,600 V). 
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Appendix H:  Standard BVM Protocol 
 
 
 
 146 
 
Appendix I: Copyright Permission Requests 
 
Dear Tiffany: 
  
On behalf of the National Heart, Lung, and Blood Institute (NHLBI) Health Information Center, 
we are responding to your request for information on the NHLBI copyright permission policy. 
  
The information contained in materials published by the NHLBI is in the public domain.  No 
further permission is required to reproduce or reprint the information in whole or in part.  
However, organizations that reproduce NHLBI publications should cite the National Heart, 
Lung, and Blood Institute as a part of the National Institutes of Health and the U.S. Department 
of Health and Human Services as the source.  This applies to printed publications as well as 
documents from the NHLBI Web site. Organizations may add their own logo or name.  We 
further ask that no changes be made in the content of the material, and that the material as well as 
any NHLBI Internet links should not be used in any direct or indirect product endorsement or 
advertising. 
  
Sincerely, 
 
 
NHLBI Health Information Center 
PO Box 30105 
Bethesda, MD 20824 
Phone: 301-592-8573 
Fax: 301-592-8563 
E-mail: nhlbiinfo@nhlbi.nih.gov 
Web site: http://www.nhlbi.nih.gov 
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Sorry for the delay--yes you have permission. 
Regards, 
Rick 
 
Richard Gersony MFA CMI 
President, Medical Illustrator 
www.medmovie.com 
 
medmovie 
167 West Main Street 
Suite 1210 
Lexington, KY 40507 
Fax:     859.225.6401 
Phone: 859.225.6400 
 
 
